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Abstract 
 
Malaria remains a devastating disease. Transmission-blocking vaccines (TBVs) are 
being considered as a promising approach to eliminate Plasmodium infection. However, 
the challenges in developing such a vaccine are paramount, since the clinically relevant 
species of Plasmodium are transmitted by a number of different Anopheles mosquito 
vectors. Through association studies, we discovered FREP1, a mosquito midgut protein 
that facilitates P. falciparum parasite transmission. Our biochemical characterization of 
FREP1 discovered that this protein is secreted as a tetramer, expressed by midgut cells 
and located in the peritrophic matrix (PM) of mosquito midgut. Molecular analysis 
revealed that FREP1 anchors parasites to the mosquito PM, assisting ookinetes as a 
midgut receptor for Plasmodium migration from the blood bolus and subsequent 
invasion of the midgut epithelium. Since FREP1 is readily accessible to antibodies co-
ingested with blood, it is a suitable antigen for targeting by TBV. Sequence comparison 
of orthologs showed that the fibrinogen-like (FBG) domain of FREP1 is highly 
conserved (>90% identical) among Anopheles species from different continents, 
suggesting that anti-FBG antibodies may block malaria transmission to all anopheline 
mosquitoes. Using standard membrane-feeding assays (SMFA), we showed that anti-
FREP1 polyclonal antibodies significantly blocked transmission of P. berghei and P. 
vivax to An. gambiae and An. dirus respectively. Furthermore, in vivo studies of mice 
immunized with purified FBG showed that our experimental TBV effectively blocks P. 
berghei transmission to An. gambiae (>75%), without triggering immunopathology or 
inducing responses against mouse or human fibrinogens. Anti-FBG serum from the 
immunized mice also reduces P. falciparum infection of An. gambiae mosquitoes by 
xiii 
more than 81% during SMFA, meeting TBV criteria for clinical trials. Finally, I showed 
that the FBG domain directly interacts with Plasmodium gametocytes and ookinetes, 
revealing the molecular mechanisms of the transmission-blocking activity of anti-FBG 
antibodies. FBG also binds to peritrophic matrix, and the N-terminal region of FREP1 
keeps FREP1 as tetramers. Collectively, our data support that FREP1-mediated 
Plasmodium transmission to mosquitoes is a conserved pathway, and that the targeting 
of the FBG domain of FREP1 will limit the transmission of multiple Plasmodium 
species to multiple Anopheles species. In summary, I reported here the establishment of 
a high-level secretion system using mosquito FREP1 signal peptide to secrete 
recombinant heterologous proteins. I have elucidated FREP1 molecular mechanisms as 
an ookinete midgut receptor that facilitates parasite invasion of the mosquito midgut, 
and I have determined that the highly conserved functional FBG domain of FREP1 is a 
broad-spectrum transmission blocking vaccine antigen.   
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Chapter 1: Introduction 
 
1.1 History and Epidemiology of Malaria 
Malaria is one of the major diseases affecting man, being first reported around 
4,000 years ago[1]. Initially, malaria was thought to be caused by ‘bad air’ (from the 
Italian mal’aria), and its causative agent was discovered in 1880 by a French army 
surgeon, Charles Louis Alphonse Laveran[1]. In the late 1890s, the heamosporidan 
parasite of the genus Plasmodium was confirmed to be the etiological agent of 
malaria[1]. Haemosporidan parasites are apicomplexan protozoans, which are 
unicellular eukaryotic cells that infect the blood of vertebrates[2]. In 1897, Ronald Ross 
first demonstrated that patients carrying malaria parasites could infect hematophagous 
mosquitoes, revealing that the female Anopheles transmit the disease[1]. To this present 
date, malaria remains as one of the world’s most devastating diseases with an alarming 
two-thirds of the world population at risk of malaria[3]. There are currently 97 countries 
with on-going malaria transmission and seven other countries in the prevention of 
introduction phase, totaling 104 countries with endemic malaria[4, 5].  
According to the recent reports from the World Health Organization (WHO), 
malaria has decreased by 50% globally and 47% in Africa in the past ten years. This 
considerable decrease is largely due to the combined efforts of insecticide spraying, 
insecticide treated bed nets, and advancement in the early diagnostics and treatment of 
disease[6, 7].   Despite this progress in combating the disease, in 2013 $2.6 billion were 
spent on a variety of malaria control programs. Despite these efforts, 198 million 
malaria clinical cases and 568,000 deaths were accounted worldwide in 2013[8]. The 
overwhelming majority of the fatalities occur in Africa, where 87% of the deaths are 
2 
children under the age of five and pregnant women[4, 8].  The current agenda for 
malaria control set by several non-governmental organizations, established malaria 
eradication as the main goal for the next 20 years and to interrupt malaria transmission 
as the focus of the eradication program[9-19]. The malaria parasite has a much more 
complex life cycle compared to viruses and bacteria, which augment its complexity. 
Bacterial and viral diseases such as (e.g. smallpox, polio, and measles) not only have 
vaccines available, but also have been completely eradicated through vaccination 
programs whereas no effective vaccine is available for any parasitic disease[20, 21]. In 
addition to the complex biology involving both a vertebrate and an invertebrate host, 
Plasmodium parasites have genomes that are much larger than those of viruses and 
bacteria[22]. As a result, their genetic make-up is extremely variable across the different 
stages of their life cycle; this variation in the parasite expressing different proteins on the 
cell surface elicits different arms of the immune system to combat the disease depending 
on whether the parasite is inside or outside of the host cells[23, 24].  Furthermore, 
antibodies raised against certain stages of malaria are not effective across other stages of 
the infection[25, 26].     
1.2 Basic Biology 
There are five major Plasmodium species that are the etiological agents of human 
malaria; P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi; P. falciparum 
and P. vivax account for 99% of the malaria cases worldwide[1, 27]. Uncomplicated 
malaria is more common in adolescents and adults in high transmission areas, whereas 
severe malaria, which mostly results from P. falciparum infections, is frequently 
observed among young children and adults who travel to areas of high malaria 
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transmission[28]. In extreme cases where the infected red blood cells are sequestered in 
the brain, cerebral malaria may occur with convulsions, followed by coma, and eventual 
death[1, 29]. There are approximately more than 30 species of Anopheles mosquitoes 
that transmit malaria worldwide, with a varying degree of efficiency[30]. The main 
malaria vector in Africa is Anopheles gambiae; however A. funestus and A. arabiensis 
are important vectors as well[30, 31]. In Asia, A.dirus and A. stephensi are responsible 
for the malaria cases[32]. In Europe A. atroparvus and in South America, A. minimus, 
A.albimanus and A. darlingi are the main transmission agents of the disease[14, 30, 33, 
34].   
To complete its complex life cycle, Plasmodium needs to infect a vertebrate and 
then a mosquito host (Figure 1). In the case of the human malaria, the vertebrate host is 
a human, although other mammals, reptiles and birds can be infected by their respective 
Plasmodium malaria-causing parasite. The basic biology of the Plasmodium parasite 
begins when an infected female Anopheles spp. mosquito takes a blood meal from 
human. The mosquito inoculates uninucleate sporozoites, the only form of the parasite 
that can infect humans, into the tissues or directly into the bloodstream. Sporozoites, as 
fast as 2 minutes and no more than 60 minutes, pass through the bloodstream and invade 
the liver where they penetrate, in the hepatic sinusoids, and could pass through the 
Kupffer cells and invade hepatocytes[20]. Sporozoites could enter several liver cells 
prior to finding the correct hepatocyte in which it can develop. The uninucleated P. 
falciparum sporozoites undergo a rapid growth yielding 10,000-40,000 liver-stage 
schizonts, with an average of 30,000 uninucleated merozoites, in a minimum of 5.5 
days[35]. The mature liver-stage schizonts exploit the host liver cell resources leading to 
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its death or ultimately the rupture and release of "sacks” called merosomes 
containing tens of thousands of uninucleated merozoites, the infectious form of the red 
blood cells. In the erythrocyte, it takes approximately 48 hours for the invading 
merozoite to develop into a mature erythrocyte-stage schizont averaging 16 uninucleated 
merozoites[36]. The parasites undergo asexual multiplication inside the erythrocytes, 
and fully mature merozoites are released from the infected erythrocyte and invade 
normal erythrocytes, initiating the cycle of intraerythrocytic-stage development, rupture, 
and reinvasion. This process results in 10-20-fold increase in the numbers of P. 
falciparum parasites in the bloodstream every 2 days[20]. This cycle characterizes all 
the clinical and pathological manifestations of malaria[36]. Erythrocyte-stage parasites 
can, alternatively, develop into sexual-stage parasites, called gametocytes.  
Plasmodium then undergoes an obligatory developmental cycle in the mosquito 
midgut, where gametocytes ingested by Anopheles spp. during a blood meal, within 
approximately 15 min (in the case of P. falciparum) egress from the erythrocytes and 
differentiate into gametes[37]. The male gametocytes undergo a significant 
transformation known as exflagellation, in which the DNA replicates to 8N and 
subsequent formation of eight haploid gametes (microgametocytes)[23]. Free 
microgametes fuse with the female gamete (macrogametocytes) forming a diploid 
zygote, which immediately experiences one round of DNA replication to become 
tetraploid[23]. This sexual multiplication of the parasite inside the mosquito gut is 
known as the sporogonic cycle. The zygote, 18-24 hours later, turns into a motile and 
elongated form, the ookinete. The motile ookinete migrates from the blood bolus to  
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Figure 1-1. Basic features of the Plasmodium life cycle.  
In order for Anopheles females to lay eggs a bloodmeal is necessary. a, In the process, 
infected females inject sporozoites, the only form of the parasite that can infect humans, 
into the bloodstream. b, Within minutes, liver cells are invaded and the sporozoites 
proliferate asexually. c, 6-7 days later, as merozoites, they invade the erythrocytes. An 
asexual 48-hour cycle within the erythrocytes, at which the disease clinically manifests 
as fever and chills, is followed by the production of male and female gametocytes. d, 
These are the only forms that can infect mosquitos during a bloodmeal, where they 
differentiate into male and female gametes and fuse to form ookinetes. e, Ookinetes 
penetrate the midgut epithelium and form oocysts that duly divide to create sporozoites. 
These migrate to the salivary glands, where the cycle of infection starts again when the 
mosquito takes another bite.  Adapted by permission from Macmillan Publishers Ltd: 
[Nature Reviews Immunology] REF. 36 © (2011).  
 
a
b
c
d
e
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invade and traverse the midgut wall by passing through the peritrophic matrix (PM), 
epithelial cells and comes to rest adjacent to the basal lamina. The ookinete undergoes a 
series of development and multiplication and differentiates into a round oocyst. Within 
10-14 days the oocyst has grown in size and undergone sporogony to produce thousands 
of sporozoites in the hemocoel of the mosquito. The sporozoites circulate within the 
haemolymph and specifically invade the salivary glands[23, 38]. When the mosquito 
bites another human, the sporozoites in the salivary glands are inoculated into the new 
host, perpetuating the malaria life cycle.     
1.3 Malaria and Immunity 
There are several natural barriers that the Plasmodium parasite encounters in 
both humans and invertebrate hosts. In mammals, the host defense against malaria 
infection relies mainly on the T-cell mediated and humoral anti-malaria response[28, 
39]. In mosquitoes, there is a complete dependence of the innate immune system, which 
refers to the ﬁrst-line host defense that serves to limit infection in the early hours after 
exposure to microorganisms[40]. 
1.3.1 Humans Immunity and Malaria 
Hepatocytes, and particularly erythrocytes, have extremely low expression of 
both major histocompatibility complexes (MHC) on the cell surface, which represents an 
optimal condition for intracellular parasites like Plasmodium. Without the MHC class I-
antigen presentation, CD8+ T cell activation does not occur, and a T cell mediated 
cytotoxic response to clear infected cells does not happen, granting the parasite an 
enormous advantage to pursue the blood stage of infection[27]. Malaria parasites are an 
obligate intracellular pathogen, which enables the avoidance from antibody-mediated 
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immune response[41]. In addition, the parasites have evolved a rapid transition from one 
cell to another, e.g. sporozoites take 10-15 min from skin to liver[42], and merozoites 
will invade a red blood cell in less than 30 s[43]. The parasite life’s strategy poses 
difficulties for the immune system, with insufficient time for antibodies to act. Due to 
the reasons mentioned above, sporozoites and immature liver-stage elicits little to no 
inflammation[44], indicating the existence of a mechanism in the parasites that turns 
their pathogen associated molecular patterns (PAMPs) in the invading parasite 
unavailable to the pattern recognition receptors in the human host (PRR)[45]. This was 
demonstrated by studies that observed inflammation responses in radiation-attenuated 
sporozoites but not in viable Plasmodium yoellii infection in BALB/C mice[46, 47]. 
After sporozoites penetration of the skin, priming by T and B cells takes place in 
the lymph nodes or in the liver, where they invade hepatocytes[41, 48]. Antibodies 
neutralize sporozoites in the skin to prevent their invasion of liver cells[28].  Natural 
Killer (NK) cell and T cell derived IFN-γ is assumed to enhance phagocytosis of red 
blood cells by macrophages[41, 49].     
Previous studies indicate that cytokines produced during Plasmodium infection 
are associated with gametocytes killing in the blood stream, due to increase of the pro-
inflammatory cytokines tumor necrosis (TNF)-α and interferon (IFN)- γ produced by the 
host immune system[50-53]. Inflammatory cytokine’s role in limiting malaria 
parasitemia is via activation of innate immune mechanisms of monocytes and 
macrophages[5]. Induction of phagocytosis and increased nitric oxide (NO) production 
by leukocytes are attributed to gametocyte inactivation and loss of mosquito 
infectivity[53, 54]. Dendritic cell (DC) encounter and recognize infected erythrocytes 
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via PRR and present to CD4+ cells and could cross-present antigen to CD8+ T cells[41]. 
Cytokines like IL-12 facilitate activation of natural killer (NK) cells, leading to IFN- γ 
production, which promotes the activation of adaptive and humoral immune responses 
via antibody subclass switching[27].  
In summary, NK cells, T cells, and phagocytes mediate the main immune events 
following Plasmodium infection by restrain of the earliest phase of parasite growth. T 
cells may limit parasitemia and antibodies clear the residual infection[28, 49].   
1.3.2 Mosquito Innate immunity and Malaria 
The peritrophic matrix, known as PM, and the midgut epithelium are the physical 
barriers to parasite invasion in the mosquito midgut. The PM formation is stimulated by 
bloodmeal and its structural composition involves proteins, glycoproteins, and 
proteoglycans that are structurally linked by chitin[55]. The PM gradually thickens and 
polymerizes reaching maximal rigidity 24 h after bloodmeal; therefore it constitutes a 
physical barrier between bacteria and other elements present in the blood bolus and the 
midgut epithelium[26, 56, 57].  The motile ookinete once egressed from the PM has to 
traverse the midgut epithelium resulting in severe damage and eventual death of the 
invaded epithelial cells. As a result, there is an increase of nitric oxide synthase 
expression[38] along with high levels of peroxidases, which in turns leads to an increase 
in midgut nitration[58]. This is thought to be a critical determinant of parasite 
recognition by the mosquito complement-like pathway[59].  
A bloodmeal containing malaria parasites, besides being sufficient to trigger 
Plasmodium immune responses prior to ookinete invasion of the midgut epithelium [60], 
also carries immune components from the human host (e.g. cytokines, leukocytes, NO, 
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and complement system) which influence parasite development inside mosquito midgut 
lumen[61-63]. In addition, there is evidence that the mosquito microbiota play a direct 
role in the activation of the mosquito immune response, due to the drastic proliferation 
that occurs immediately after bloodmeal[64-66]. Contributions of mosquito tissues to 
the anti-plasmodium immune response that limits Plasmodium development are multi-
faceted involving multiple mosquito tissues e.g. fatbody (systemic immunity, humoral 
immunity via antimicrobial peptides)[67], midgut and salivary glands (local epithelial 
immunity, pathogen recognition and physical barrier)[60, 68], and hemocytes (cellular 
immunity, circulating immune components and phagocytosis)[69, 70].  
Expressions of immune markers and mRNA levels of antimicrobial peptides e.g. 
defensin, a putative serine protease (ISPL5), a putative Gram-negative binding protein 
(GNBP), a chitinase-like domain containing protein (ICHIT), a lectin-like protein 
(IGALE20) and nitric oxide synthase (NOS) increase in the midgut 24 h post 
Plasmodium infection[38, 71-73]. These innate immune components are responses 
directed to eliminate most invading parasites. Therefore, Plasmodium parasites 
encounter major obstacles in the midgut tissue stage of mosquitoes where most parasites 
are cleared by the innate immune system[23, 33, 55]. In the event the ookinete 
successfully traverses the midgut epithelium, the mosquito host immune system has two 
mechanisms against the invading ookinete: an ‘early-phase’ and a ‘late-phase’ response. 
The early-phase response mechanism relies on the activation of complement-like system 
after interaction of the soluble immune proteins that circulate in the haemolymph 
following parasite invasion of the luminal side of the mosquito midgut[69, 74].  The 
‘late-phase’ response attack comes upon the ookinetes that survive the ‘early-phase’ 
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immune response and it is controlled by the signal transducer and activator of 
transcription (STAT)-A or STAT-B. Knock down experiments showed that silencing of 
STAT-A or STAT-B increased oocysts survival through decreased production of 
NOS[75].   
The Toll and Imd receptor immune signaling pathways are two conserved 
immune pathways in mosquitos for host defense that induce the production of effector 
molecules, of which antimicrobial peptides are the most prominent [76, 77]. RNAi 
silencing experiments are the strongest evidence of the involvement of these pathways in 
Plasmodium immunity[60, 78]. Survival of ookinetes in the midgut epithelium has been 
shown to depend on the action of agonists and antagonists. Recent studies have 
identified infection-inducible putative pattern recognition receptors, e.g. TEP1, LRIM1, 
APL1, and FBN9 that can mediate killing of ookinetes in the midgut epithelium[69, 79, 
80]; in contrast, the c-type lectins CTL4 and CTLMA2, and Fibrinogen-like protein 1 
(FREP1) can protect the ookinetes from destruction[81, 82]. The synergistic effects of 
the physical barriers and the immune components of the mosquito’s midgut result in a 
bottleneck of the Plasmodium lifecycle, with a drastic decrease in the parasite 
population [23, 83]. In fact, in the majority of endemic areas only a small portion of the 
mosquito population carries the parasite[84-87]. Thus, the mosquito midgut stage of 
parasite development constitutes an optimal target for malaria interruption vaccines, 
namely for two reasons: the potential to enhance transmission blockade by exploiting the 
natural occurrence of a several fold decrease in the parasite population; and, due to the 
generic innate immune effector mechanism of mosquitoes, there is no highly antigen-
specific immune response, which results in low polymorphism on mosquito sexual 
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parasite stage surface proteins, contrary to the asexual human stages[88].  
1.4 Current Scenario of Malaria Control 
Three main reasons could account for the current status of malaria infections 
around the world: first, there are no drugs available that can cure infected humans on a 
routine basis and on a large scale. In addition, parasites have developed drug resistance 
against most common anti-malarial drugs, including the recent developed family of 
antimalarial drug – the artemisinins, extracted from the Qinghaosu plant (Artemisia 
annua) – and quinine from the cinchona tree (Cinchona spp.,)[7]. This resistance is 
attributed to the large genetic and genomic plasticity of the parasites[89, 90]. Second, 
the rapid spread of insecticide resistant mosquitoes[91-94], in addition to a lack of 
environmentally, large-scale effective vector control programs[13]. Third, there are no 
commercially available vaccines that can offer protection against the protozoan 
Plasmodium, the causative agent of the disease[95]. Morphologically, malaria parasites 
are complex with many antigenic targets, which often result in challenges to elicit a high 
immunogenic response; thus an alternative approach based on subunit vaccines has been 
adopted[96, 97]. Subunit vaccines constitute individual recombinant parasite proteins 
administered either as monovalent or combined preparations incorporated with other 
vectors and adjuvants in order to heighten immune responses[27, 98, 99]. The WHO set 
the goal in 2006 to license an efficacious vaccine with >50% protection by 2015[14, 
100]. However, only one candidate vaccine RTS, S/AS02A has obtained licensure. This 
vaccine is far from ideal, having demonstrated only 46% efficacy[101-105]. Activity of 
this potential vaccine is based on repeat regions and T-cell epitopes of circumsporozoite 
protein (CSP), and it is the primary focus of many phase 3 clinical trials among children 
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1.5 The call for eradication  
 
Figure 1-2. Malaria vaccines target different stages of the parasite life cycle [97]. 
Vaccines against the liver-stage, where following the bite (1) of an infected mosquito, 
the vaccine would prevent sporozoites from invading liver cells (2-4). This pre-
erythrocytic vaccine is also called vaccine that interrupts malaria transmission (PE-
VIMT), which interrupts transmission from mosquitoes to humans. Vaccines against the 
asexual blood stage, which would interfere with the disease-causing stages once the 
infection had entered the bloodstream (5-6). Last, vaccines targeting sexual stages of the 
life cycle (gametocytes 7, gametes 8 and ookinetes 9) or mosquito antigens to prevent 
the development of infectious sporozoites (10). This vaccine aims at interrupting 
transmission from infected humans to mosquitoes and it is also called a sexual, 
sporogonic, or mosquito stage VIMT (SST-VIMT). Reproduced from the PATH website 
at www.path.org, [October 25, 2016]. 
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in the sub-Saharan Africa[106, 107].   
The venture to control malaria has two main approaches: a direct approach, 
which consists of using vaccines and drugs to cure it and the indirect approach, 
which focuses on vector control strategies[95]. Given the current scenario described 
above, there is an urgent need to develop and deploy drugs and vaccines to prevent 
transmission of malaria from human to mosquito, as a manner to interrupt the 
appearance of resistant or multiresistant Plasmodium genotypes[108, 109]. A 
transmission-blocking vaccine is seen as an essential tool in the malaria elimination and 
eradication efforts, including prevention of reintroduction of the disease, and when 
combined with other control measures, TBVs could assist a given geographic region in 
overcoming the threshold from control to elimination stage[12-14, 110].   
Vaccines developed against the malaria parasite potentially target three stages of 
the development (Figure 2): vaccines against the liver-stage, where following the bite of 
an infected mosquito, the vaccine would prevent sporozoites from invading liver cells 
preventing clinical disease as well as transmission [14, 111]; those against the asexual 
blood stage targeting merozoites or infected red blood cells, which would interfere with 
the disease-causing stages once the infection had entered the blood[112, 113]; and those 
against the parasites sexual stages and the stages inside the mosquito midgut, aimed at 
preventing parasites from infecting the arthropod vector[9, 33, 114]. The latter type of 
vaccine is designed to reduce or block the transmission of malaria in human and 
mosquito populations; thus they are termed malaria transmission blocking vaccines 
(TBVs)[20, 33, 115]. TBVs are alternative vaccines that target sexual erythrocytic and 
early stage mosquito antigens, preventing the spread of the pathogen from an infected 
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individual to a noninfected individual.  The principle of action is based on the antibodies 
raised against antigens expressed in the sexual stages of the Plasmodium parasites or 
antigens in the mosquito itself[116, 117]. The antibodies are presented to the mosquito 
in the bloodmeal, which once inside the mosquito midgut, target their antigens leading 
to interruption of the cascade of events that leads to the transmission cycle of the 
parasite[118, 119].  
TBVs are commonly labeled as being altruistic vaccines since these vaccines do 
not offer clinical protection for the recipient but rather establish herd immunity[33]. An 
understanding of the biology and the epidemiology of malaria transmission is primordial 
for comprehending the practical employment and the potential impact of TBVs[14]. In 
order for malaria transmission to occur, an interaction must take place between an 
appropriate Anopheles mosquito and a human population that resides within a strictly 
limited distance from the aqueous breeding site of these mosquitos[114]. Thus, malaria 
transmission is a local feature of a given area, in which practices to reduce or exclude 
malaria transmission in small areas of up to 1 km of radius is attainable with measures 
that include drainage, residual spraying, and TBV[114]. Indeed, TBVs are intended to 
stop transmission in local community where their deployment would benefit members of 
the same household[33, 100]. In additional to their potential to reduce malaria 
transmission rates in human population, malaria TBVs could prolong the effective life of 
other malaria vaccines as they could prevent the scape of the parasites from human host. 
In this manner, if used in combination with liver and blood stage vaccines, TBVs could 
synergistically enhance the efficacy of these individual vaccines by preventing or 
reducing the spread of parasites that became resistant to such vaccines[14, 15, 41]. The 
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challenges involved in the development of TBV candidates are antigens with poor 
immunogenicity, epitope conformation dependence and low conservation of antigen 
across different species. [20, 33, 60, 114, 118, 120]. In addition, since TBV vaccines do 
not confer individual protection but ‘herd immunity’, there is a possibility that 
regulatory processes will be more complex, as this may influence the cost-benefit 
analysis made by governments and funding agencies as well as its acceptance at the 
community level[14, 41, 100].  
Finding target molecules on parasite surface or in mosquito midguts is needed 
for developing vaccines against malaria. 
1.6 Genomics and Vector Control 
Genetic association studies are used to find candidate genes or genome regions 
that contribute to a specific disease by testing for a correlation between disease status 
and genetic variation[121]. Single nucleotide polymorphisms (SNPs) are particular base 
pair positions in the genome where alternative nucleotides distinguish individuals[122]. 
The genome of Anopheles gambiae is 278 million base pairs long and it is replete of 
nucleotide polymorphisms with an average of 1 SNP per 247 base pairs[123]. According 
to Aguilar et al (2010) the capability of the mosquito to transmit malaria to humans in a 
large range of ecological settings can be explained by this high density of SNPs in their 
genome.  The authors affirmed, “ …this large numbers of molecular and chromosomal 
polymorphisms provide a great evolutionary potential as a reservoir of genetic 
variability”[124]. Genetic variation in mosquito populations affects the mosquitoes’ 
susceptibility to P. falciparum infection[125-127], insecticide resistance[122], and other 
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traits of interest. Genome wide association studies focusing on mosquito immunity have 
contributed to population management and disease control[128].  
Through direct genome-wide association studies in wild mosquitoes from 
malaria-endemic regions in Africa, we recently identified a mosquito gene, fibrinogen-
related protein 1 (FREP1) that is implicated in Plasmodium infection in 
mosquitoes[125]. Specific genetic polymorphisms in FREP1 are significantly associated 
with P. falciparum infection intensity levels in wild An. gambiae populations from 
Kenya. The FREP1 protein is a member of the fibrinogen-related protein family (FREPs 
or FBNs) that contains a highly conserved C-terminal interacting fibrinogen-like (FBN) 
domain[80]. In vertebrates, fibrinogen molecules usually associate as hexamers and are 
comprised of two sets of disulfide-bridged α, β and γ chains that participate as a 
principal component of both cellular and fluid coagulation[129]. In invertebrates, 
FREPs/FBNs are common pattern recognition receptors (PRR)[130, 131] responsible 
mainly for initiating innate immune responses[132, 133]. For instance, tachylectin 
proteins in the horseshoe crab perform an effective host defense by recognizing bacterial 
lipopolysaccharides[134]. Since mosquitos lack an antibody-mediated response, they 
rely on PRRs to initiate innate immune response against pathogens[135, 136]. Previous 
work examining the role and function of FREP/FBN family members in Anopheles 
mosquitoes has shown that two family members, FBN9 and FBN30, appear to restrict 
Plasmodium infection of midgut epithelial cells[80]. Indeed, silencing the expression of 
either FBN9 or FBN30 in mosquitoes increased Plasmodium infection[80, 125]. Here, I 
report the role and function of a third FREP/FBN family member, FREP1, during P. 
falciparum infection of Anopheles mosquitoes. In contrast to FBN9 and FBN30 that 
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inhibit Plasmodium infection, our results[72, 114] showed that FREP1 is an important 
host factor that promotes infection of mosquito midguts by the major human pathogen, 
P. falciparum[82]. Altogether, our data reveal new insights into Plasmodium-Anopheles 
interactions and identify FREP1, a highly conserved mosquito antigen across malaria 
vectors, as a promising target for the development of vaccines that interrupt malaria 
transmission. 
1.7 Summary of Dissertation 
In my graduate studies, I investigated the biological and molecular function of 
our newly discovered molecule FREP1 that is related to malaria transmission in 
mosquitoes, and my contribution is finding the localization of endogenous FREP1 in 
mosquito midgut peritrophic matrix. Next, I constructed an expression vector using 
FREP1 signal peptide-directed secretion system to efficiently secrete heterologous 
proteins from insect cells. Then, I proved that the FBG is the functional domain of 
FREP1 having a dual role assisting Plasmodium invasion of mosquito midgut by directly 
binding to the parasite and the PM, facilitating ookinete penetration of the midgut 
epithelia. Finally, I demonstrated that the FBG domain could be used as a vaccine target 
to interrupt transmission of multiple Plasmodium species to different Anopheles 
mosquitoes.  
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Chapter 2: Anopheles FREP1 Signal Peptide-Directed Secretion of 
Recombinant Proteins from Insect Cells 
 
2.1 Introduction 
Prokaryotic expression system, even though it has the advantage of a rapid 
growth rate and relatively low cost, in most circumstances recombinant proteins cannot 
be secreted into the extracellular medium [1]. Moreover, formation of inclusion bodies 
and the lack of post-translational modifications (e.g., glycosylation, phosphorylation, 
and disulfide bond formation) hinder the bacterial expression system for production, 
especially, of secreted proteins that require those modifications as well as proper folding 
for biological activity [2, 3].  Insect and mammalian cells have been the expression 
systems of choice for functional recombinant proteins for a wide range of 
applications[4-6]. Whilst mammalian cells cultures can be complicated, time consuming 
and expensive [7], baculovirus expression systems in insect cells presents a series of 
biological and engineering disadvantages[8, 9]. The cabbage looper ovarian cell-derived 
High Five cell line (BTI-TN-5B1-4), developed by the Boyce Thompson Institute for 
Plant Research (Ithaca, NY)[10-12] has proven to be particularly effective in producing 
abundant levels of biologically active recombinant proteins of different sizes and 
organisms[13-15]. However, it takes a considerable effort to obtain highly purified 
recombinant proteins expressed in the cytosol of cells. Therefore, high expression level 
and convenient purification of heterologous eukaryotic proteins of interest are critical 
for biotech industry and research labs to generate affordable active proteins. 
Signal peptides have an essential role in protein export and membrane insertion 
of secretory and membrane proteins[16, 17]. Different signal sequences have been 
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observed assisting in the transport of their target proteins through common pathways and 
they can be interchanged between proteins, and even proteins from different origins[18, 
19]. Furthermore, it has also been noted that these interchangeable signal peptides can 
lead to increased protein secretion[20].  Proteins secreted to extracellular media simplify 
the purification process, especially in serum-free insect cell cultures.   
FREP1 is a blood induced secreted protein in mosquito midgut peritrophic 
matrix and is able to facilitate P. falciparum infection in An. gambiae. Previously, we 
demonstrated that FREP1 can be efficiently secreted to the culture medium.  [21]. In this 
report, we compared FREP1 signal peptide to Apis mellifera melittin signal peptide [22], 
and An. gambiae FBN30 signal peptide for their ability to secrete a foreign protein in 
High Five insect cells.  In this study, we also examined the secretion of normally non-
secreted and secreted proteins using the An. gambiae FREP1 signal peptide in High Five 
cells[23]. The results reported here showed a substantial increase in the overall level of 
secretion of the recombinant proteins when using FREP1 signal peptide.  Conceptually, 
our data support that both signal peptide and intrinsic sequences of mature proteins 
determine secretion efficiency. 
2.2 Material and Methods 
2.2.1 Cloning signal peptides into expression vector 
The expression vector pIB/V5-His (Life Tech, Grand Island, NY) was used in 
order to analyze the secretion efficiency of the mosquito FREP1 signal peptide via the 
InsectSelectTM system[23] (Invitrogen). The vector is under the control of the 
immediate-early promoter OpIE2 from the baculovirus Orgyia pseudotsugata 
multicaspid nuclear polyhedrosis virus (OpMNPV), which, allows for constitutive 
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protein expression in High Five cells (Invitrogen), among other insect cell lines. 
Oligonucleotides containing a Kozak consensus sequence and the respective sequence 
coding for the Anopheles gambiae FREP1 signal peptide were synthesized (Live 
Technologies, Carlsbad, CA) (F FREP1 SigP and R FREP1 SigP 1, 2, or 3, see Table 1). 
The signal peptide sequence and cleavage site of FREP1 were determined with the 
signal peptide prediction server SignalP ver. 4.1[32]. Three different linker regions were 
cloned into the expression vector, with a multiple cloning site with the following 
endonucleases restriction sequences BamH I, Sac I, Spe I, and Xho I added to the 3’ end 
of the signal peptide for further cloning. The signal peptide of FREP1 and its fibrinogen-
like domain (FBG) were amplified using primers of F FBG Domain and R FBG Domain 
(Table 1) from the previously constructed pIB-FREP1/V5-His vector [21]. 
Oligonucleotides containing the Kozak consensus and the well-characterized honeybee 
melittin (HBM) signal peptide with its cleavage site[22] were synthesized  with oligers 
of F HBM-pIB and R HBM-pIB (Table 1) through Life Technologies (Carlsbad, CA) 
and annealed in order to generate a dsDNA with a 5’ GATC (sense strand) and a 5’ 
TTAA (antisense strand) extension compatible with overhangs created by restriction 
endonuclease BamH I (NEB, Ipswich, MA) and EcoRI (NEB). The pIB/V5-His vector 
(Life Tech) was digested with the restriction endonucleases BamH I and EcoRI and the 
annealed oligonucleotides was cloned into this vector.  
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Table 2-1. Primers list for cloning signal peptides into pIB/V5-His. 
Primer Name Nucleotide Sequence 5’-3’ 
pIB/FREP1 SigP /V5-His 
F FBG pQE30 5’-ACGCATGCCACGAGTACGAGTCGATC-3’ 
R FBG pQE30 5’-TGCAAGCTTGTACTCGTGCTCGACCGACTC 
F FREP1 SigP 5’-GCGAAGCTTCACCATGGTGAATTCATT 
R FREP1 SigP 1 5’-TACGCTCGAGGTCGACACTAGTGGATCCGTTA CTGCTGCTGCTGCTG-3’ 
R FREP1 SigP 2 5’-TACGCTCGAGGTCGACACTAGTGGATCC CCCAGACACTGCACCGTT-3’ 
R FREP1 SigP 3 5’-TACGCTCGAGGTCGACACTAGTGGATCCGTTC AGGGCAGT-3’ 
F FBG Domain 5’-GATCCACTAGTGTCGACCTCGAGGAGTCGAT CATCAAC-3’ 
R FBG Domain 5’-ACTCTAGAGTCGGCCGGCGGGCAATCATC ATGT-3’ 
F AgFBN30CDS 5’-ATGCTGCTCGCAACAGTTTC-3’ 
R AgFBN30CDS 5’-CTACGGTGCACTACGAAGCC-3’ 
F FREP1SigP/FBN30 5’-AGCGTCGACCAACTCCTTGCCGCTAGTGTT-3’ 
R FREP1SigP/FBN30 5’-ACGTCTAGAGTCGGTGCACTACGAAGCCGA-3’ 
F FBP4 5’-CGGGATCCATGAGAGAAGTAATAAGTATAC-3’ 
R FBP4 5’-GCTCTAGAATAGTCTGCCTCATATCCTTC-3’ 
pIB/HBM/V5-His 
F HBM-pIB 
5’-GATCCCACCATGAAATTCTTAGTCAACGTTGC 
CCTTGTTTTTATGGTCGTATACATTTCTTACATCT
ATGCGGATCTAG-3’ 
R HBM-pIB 
5’-AATTCTAGATCCGCATAGATGTAAGAAATGTA 
TACGACCATAAAAACAAGGGCAACGTTGACTAA
GAATTTCATGGTGG-3’ 
F HBM-FBG 5’-TCAGAATTCGAGTCGATCATCAAC-3’ 
R HBM-FBG 5’-ACTCTAGACTCGGCCGGCGGGCAATCATCA TGT-3’ 
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2.2.2 FBG domain cloning, expression and purification from E. coli  
The FBG fragment was amplified with the gene specific primers of F FBG 
pQE30 and R FBG pQE30 (Table 1) from the full-length coding sequence of An. 
gambiae FREP1, as described previously [21]. The PCR fragment was cloned into 
pQE30 vector according to the manufacture’s instructions (Qiagen, Hilden, Germany) 
and transformed into the E. coli strain JM109 (Promega, Madison, WI). PCR analysis 
and DNA sequencing further confirmed the ampicillin resistant colonies. The positive 
clones were then transformed into E. coli strain M15[pREP4] (Qiagen) competent cells 
and induced with 1mM isopropyl-1-thio-β-D-galactopyranoside at room temperature. 
The recombinant FREP1 FBG protein was purified on a Ni-nitrilotriacetic acid column 
(Qiagen) and the eluted fractions were resolved on 12% SDS-PAGE gel and visualized 
by Coomassie blue staining. All fractions containing protein were then combined and 
protein concentration was determined using the Bradford protein assay. 
2.2.3 Cell Culture  
High FiveTM (BTI-TN-5B1-4) cells[10, 33] were routinely maintained at 27ºC in 
Express Five® Serum Free Medium (SFM) (Invitrogen) supplemented with 200mM L-
glutamine (Sigma-Aldrich) in adherent culture. In order to establish stable cell lines, 
High Five cells were seeded into six-well culture plates (35mm diameter) at 40-60% 
confluent (5 x 105 cells/mL) (2.5mL/well), and transfected for 4 hours with 1mL of 
transfection solution containing 5µL Cellfectin® Reagent (Invitrogen) and 2.5µg of 
plasmid DNA in Express Five® SFM medium. Forty-eight hours after transfection, the 
culture medium was replaced with fresh medium containing 50µg/mL blasticidin (BSD) 
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(Invitrogen). Heterogeneous populations of transfected cells expressing recombinant 
protein were obtained by weekly sub-culturing in six-well plates in the presence of 
50µg/mL BSD. Cell counts and viability were determined using trypan blue exclusion 
method.     
2.2.4 Expression of Heterologous Proteins in Insect cells 
Secretion vectors containing the FREP1 signal peptide were used for cloning 
different genes to test their expression levels. The FBG domain of FREP1 was cloned as 
described above. FBN30 was obtained by RT-PCR with gene specific primers (F 
AgFBN30CDS and R AgFBN30CDS, Table 1) from An. gambiae mosquitoes. FBN30 
PCR product containing its native signal peptide was cloned into pIB/V5-His vector 
(Life Technology, Grand Island, NY). For comparative expression, a FBN30 without its 
signal sequence was amplified with primers of F FREP1SigP/FBN30 and R 
FREP1SigP/FBN30 (Table 1) and cloned into the expression vector pIB-FREP1 SigP-
V5/His. Similarly, α-tubulin-1 (plasmodb gene ID PBANKA_0417700)[34] was 
amplified with gene specific primers of F FBP4 and R FBP4 (Table 1) from Plasmodium 
berghei ANKA stain by RT-PCR, and cloned into the plasmid. After being amplified in 
E. coli DH5α, the plasmids were purified using GenElute Endotoxin-free plasmid 
preparation kits (Sigma, USA). The purified recombinant plasmids were transfected into 
40-60% confluent High Five cells. To assist plasmid transfection into cells, Cellfectin® 
reagent was mixed with each individual plasmids (1µL Cellfectin/µg plasmid) in 5-6 mL 
Express Five® SFM medium in a 25cm2 CELLSTAR® cell culture flask (Greiner Bio-
One) at 27°C. Media and cells were collected 3-5 days post transfection and analyzed 
for expression of recombinant protein.  
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2.2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
After transfection, cells were assayed for expression of the heterologous protein. 
Transfected culture media supernatant and cell lysate (50µL) were used to coat 96-well 
plate (Brand, Wertheim, Germany). Following overnight incubation at 4ºC, each well 
was then incubated with the following solutions: 150 µL blocking buffer (2.5% BSA 
and 2% Normal goat serum in PBS) for 1.5 hours, 50 µL of mouse monoclonal anti-His 
antibody (1:1,000 dilution with blocking buffer) for 1 hr at RT and 50 µL of alkaline 
phosphatase-conjugated goat anti-mouse IgG (1:20, 000 diluted in blocking buffer) for 
45 min at RT. The wells were washed with PBST (PBS with 0.2% Tween-20) three 
times between incubations. Plates were developed with 50 µL of pNPP solution (Sigma-
Aldrich, St. Luis, MO) and the absorbance at OD405 was measured using an Epoch 
Microplate reader (Biotek).  
2.3 Results 
2.3.1 Expression of recombinant FBG protein in E. coli and insect cells 
FREP1 containing 738 amino acids mediates Plasmodium invasion in 
mosquitoes, and fibrinogen-like domain (FBG) is a functional domain, which is at the 
FREP1 C-terminal spanning from amino acids 463-688. We cloned the FBG domain in 
pQE-30 plasmid and expressed it in E. coli. After breaking the cells by sonication, 
results showed that the expressed recombinant FBG protein was insoluble in PBS (Fig 
2-1A). To obtain soluble functional protein, the FBG fragment was cloned into pIB/V5-
His plasmid and expressed in High Five cells. SDS-PAGE showed that FBG was 
expressed in the cytoplasm at very low levels (<0.1µg/mL, Fig 2-1B). Due to low 
expression and high contamination, it is an arduous task to purify FBG. 
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2.3.2 Evaluation of secretion efficiency of two signal peptides of insect origin in 
insect cells 
To increase the production and facilitate the purification, we modified pIB/V5-
His by adding a HBM signal peptide sequence at the beginning of the multiple cloning 
site- linker region, to generate pIB-HBMSigP/V5-His (Fig 2-1C). The high expression 
levels of the HBM signal peptide has been demonstrated previously [24]. The coding 
region for HBM was generated through total synthesis (F HBM-pIB and R HBM-pIB, 
Table 2.1), and inserted into polyclonal sites (Fig 2-1C). Then the FBG fragment was 
obtained through PCR using the F HBM-FBG and R HBM-FBG primers (Table 2.1). 
After digestion by restriction enzymes, FBG was inserted into this modified plasmid 
adjacent to the HMB signal peptide (Fig 2-1C). The plasmid was transfected into High 
Five cells, and recombinant FBG was successfully secreted into the culture medium. The 
transient expression levels were kept stable after 48 hours and were consistently 
expressed with the stable cell lines as well (Fig 2-1D).  
We then substituted HBM signal peptide with FREP1 signal peptide to secrete 
recombinant FBG fragment (Fig 2-1C) from High Five. This plasmid was also 
transfected into High Five cells. After incubation for two days, 10 µL supernatant were 
loaded on SDS-PAGE. The Coomassie blue stained-gel exhibited a denser band from 
FREP1 signal peptide guided secretion than that from HBM signal peptide (Fig 2-1D 
and 2-1E). Furthermore, the secreted recombinant FBG protein was quantified by 
ELISA using anti-FBG polyclonal antibodies, and the results revealed that FREP1 signal 
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peptide secreted more than 10-fold of FBG protein in comparison to HMB signal 
peptide (Fig 2-1F). 
 
Figure 2-1. Expression of heterologous An. gambiae FREP1 FBG domain in E. coli 
and insect cells. 
 
 (A) FBG is insoluble after induced expression in E.coli showing on Coomassie-stained 
12% SDS-PAGE gel. Lanes: 1: cells before induction; 2: cells induced; 3: cell lysate 
pellet; 4: cell lysate supernatant. (B) Recombinant FBG expressed in High Five cells. 
Lanes: 1: cell lysate; 2: Ni-NTA purified FBG (28.2kDa) from cell lysate. (C) DNA 
plasmid map of the pIB-FREP1 SigP/V5-His.  (D) FBG was secreted from High Five 
via HBM signal peptide.  (E) FBG was secreted from High Five via FREP1 signal 
peptide. Lanes: 3,5: culture supernatant; 4,6: 10X concentrated culture supernatant. (F) 
ELISA assay shows higher recombinant FBG secretion was achieved through FREP1 
signal peptide compared to HBM’s signal peptide. 
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2.3.3 The length of linker region does not affect FBG expression 
  The signal peptidase cleavage site of FREP1 signal peptide was predicated to be 
located at the position 22 (Serine) and 23 (Threonine). We engineered three different 
lengths of amino acids (5, 9 and 22) at the linker region between the signal peptide and 
the FBG domain (Fig. 2-2A). After expression in High Five cells, all constructs resulted 
in secreted FBG proteins into the culture medium. No significant difference in 
expression levels of the recombinant FBG protein among constructs was observed as the 
linker region varied from 5 amino acids to 22 amino acids (Fig. 2-2B), which indicates 
that the size of linker regions has no detectable effect on the expression of the FBG 
recombinant protein. We also expressed the full length FREP1 under the same condition 
(Fig. 2-2A), and expression level of full-length FREP1 is much higher than the others 
(Fig. 2-2B). This indicates that intrinsic mature proteins as a whole influences the 
protein secretion efficiency. 
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Figure 2-2. Various length of linker between signal peptide and mature FBG does 
not influence the secretion efficiency of FBG. 
 (A) Four different lengths of amino acid sequences from FREP1 N-terminus were 
added between signal sequence and FBG. (B) Secreted FBG in culture medium was 
quantified by ELISA. Lanes: Ctr: cells with empty vector; 1, 2, 3: cells containing vector 
with five, nine, and 22 extra amino acids at cleavage site respectively. Lane 4: full-
length FREP1. 
 
2.3.4 FREP1 signal peptide outperforms a mosquito FBN30 native signal peptide in 
recombinant expression of FBN30 
It has been indicated previously the dependence of a protein on its original signal 
peptide for its proper synthesis and expression [25]. To demonstrate that the high 
secretion levels mediated by FREP1 signal peptide are not restricted to FBG fragment, 
we cloned a mosquito gene FBN30 (AGAP006914) into the plasmid pIB-
FREP1SigP/V5-His (Fig 2-1C). FBN30 was previously found to be related to malaria 
infection in mosquitoes [26], and it is a secreted protein endogenously. Therefore, we 
constructed two pIB/V5-His expression vectors to secrete recombinant FBN30 protein: 
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one used FBN30 native signal peptide and the other used FREP1 signal peptide.  The 
two plasmids were used to express FBN30 in High Five cells under the same expression 
conditions. Ten µL concentrated from ~0.25 mL cell culture medium supernatant was 
loaded to SDS-PAGE followed by staining or western-blotting, detected by anti-FBN30 
polyclonal antibodies. Results from Coomassie blue-stained SDS-PAGE gel and 
Western blot show that both systems secreted recombinant FBN30 protein. FREP1 
signal peptide secreted higher amount of FBN30 protein than FBN30 native signal 
peptide. The recombinant FBN30 expressed with its native signal peptide is barely 
detectable (Fig. 2.3A) whereas recombinant FBN30 expressed with the FREP1 signal 
peptide is promptly detectable (Fig. 2-3B). Less than 0.1 µg/mL of recombinant FBN30 
was recovered from expression with its native signal peptide and could only be detected 
in the Western blot (Fig. 2-3A), whereas recombinant FBN30 expressed with FREP1 
signal peptide was about 10µg/mL (Fig. 2-3B). This result supports our hypothesis that a 
signal peptide of an endogenous protein must play a role to regulate a protein 
expression. 
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Figure 2-3. Secretion of recombinant FBN30 protein using FREP1 signal peptide is 
higher compared to its original signal peptide. (A): Recombinant FBN30 was 
secreted into culture medium using the native signal peptide. Lane 1: Coomassie-stained 
SDS-PAGE gel of 10µL sample of Ni-NTA purified FBN30 from 25X concentrated 
supernatant culture media; lane 2 Immunoblotting of gel shown in lane 1. (B): 
Recombinant FBN30 was secreted in culture medium through FREP1 signal peptide. 
Lane 1: 10µL sample of Ni-NTA purified FBG from ~0.25mL culture supernatant; lane 
2 Immunoblotting of gel shown in lane 1. 
 
2.3.5 Evaluation of FREP1 signal peptide expressing a non-insect cytoplasmic 
protein 
It is important for the applicability of the signal peptide to be compatible with a 
broad range of heterologous proteins. In order to determine the potential of the mosquito 
FREP1 signal peptide to secrete a cytosolic protein into the extracellular medium, we 
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transfected High Five cells with the secretion vector fused with the Plasmodium berghei 
protein α-tubulin-1 (PBANKA_0417700). The recombinant α-tubulin-1 protein 
expression was analyzed two days post transfection by ELISA. As shown in Fig. 2-4, the 
FREP1 signal peptide resulted in the extracellular secretion of a non-secreted 
Plasmodium protein. The expressed proteins were completely secreted since we did not 
detect any trace amount of the protein. This observation supports the ability of FREP1 
signal peptide to target foreign non-secreted proteins for secretion in High Five cells 
expression system.  
2.4 Discussion 
High production and easy purification are two important criteria to express heterologous 
proteins in eukaryotic cells. Therefore, establishing a serum-free insect cell secretion 
system that can secrete a protein of interest has values. It has been previously 
demonstrated that protein secretion can be improved by alternative signal peptides [27, 
28]. Initially, we attempted to secrete FBG protein using well-characterized HBM signal 
peptides. Although the recombinant protein was detected in culture medium, but the 
expression level is very low. To resolve the problem, we constructed FREP1 signal 
peptide-directed protein secretion plasmid, and successfully secreted 6µg/mL of active 
FBG recombinant protein in a serum-free adherent culture in two days, which is more 
than 10-fold higher than HBM signal peptide. 
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Figure 2.4. Secretion of P. berghei tubulin, a cytoplasmic protein using this system. 
Lanes: Ctr: culture medium with empty vector; P: cell pellet with expression vector; S: 
culture medium with expression vector. ELISA was used to detect expression of α-
tubulin-1 and its product concentration was determined via standard curve.  
 
 Furthermore, we studied the secretion efficiency related to different signal 
peptides, varying length of the linker regions, and different sources of proteins. In this 
study, signal peptides from three different genes (HBM, FREP1 and FBN30) were 
studied. For the same recombinant protein, a protein led by FREP1 signal peptide 
resulted in secretion levels about 10-fold higher than HBM signal peptide or 100-fold 
greater than FBN30 signal peptide. Thus, signal peptides have an immense impact to the 
protein production. Second, previous studies have suggested that the secretion efficiency 
of signal peptides could be affected by the amino acid sequence downstream of signal 
peptide, particularly at cleavage sites [29, 30]. By keeping the same cleavage site, our 
results indicate that the length of amino acids from 5 to 22 amino acids at linker regions 
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does not affect FBG protein secretion. However, the secretion of full length of FREP1 
(441 amino acids between signal peptide and FBG domain) is much higher than the FBG 
alone. This result indicates that a whole mature protein instead of a domain also 
determines secretion efficiency.  
 It is notable that protein secretion of FBN30 is lower under its own signal 
peptide than FREP1 signal peptide. Therefore, the signal peptide must be one of 
regulatory points for expression of endogenous proteins inside organisms, as a means to 
respond to the environment. Mutations within signal peptides could thus affect secretion 
levels of a given functional protein and consequently the organism trait. This is 
consistent to our previous findings of a naturally occurring mutant of FBN30 signal 
peptide, resulting in low expression of FBN30 and rendering mosquitos susceptible to 
Plasmodium falciparum infection, contrary to the refractoriness observed in the higher 
expressed FBN30 in mosquitoes harboring non mutated copies of the gene [26].    
 In summary, we reported here An. gambiae FREP1 signal peptide-directed 
secretion system that is able to efficiently secrete heterologous proteins from insect 
cells. The signal peptides and whole intrinsic proteins have an immense impact on 
protein secretion efficiency. 
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Chapter 3: Secreted FREP1 Localizes in the Peritrophic Matrix of 
Anopheles gambiae Mosquitoes and Interacts with sexual stage 
Plasmodium Parasites1 
 
3.1 Introduction  
Malaria remains a worldwide public health crisis, and Anopheline mosquitoes 
transmit malaria pathogens, of which P. falciparum is the most dangerous species(1). 
Female mosquitoes require bloodmeal for egg production (2). Feeding on Plasmodium-
infected blood can result in the ingestion of male and female haploid gametocytes that 
fuse to form diploid ookinetes: a process that initiates Plasmodium infection of the 
mosquito vector.  Ookinetes start invading mosquito midgut epithelial cells between 12 
to 24 hours after a bloodmeal (3). Un-fused gametocytes or ookinetes located near the 
periphery of the blood bolus in the mosquito midgut are susceptible to the attack by 
diverse digestive proteases and bacteria (4-6), while gametocytes and ookinetes inside 
the blood bolus are protected by blood. However, mature ookinetes must cross and exit 
the blood bolus in order to initiate invasion of epithelia. Mosquito blood feeding 
regulates the gene expression (7,8) and also stimulates the formation of the peritrophic 
matrix (PM) inside the midgut (9). The newly formed PM completely surrounds the 
ingested blood, separating the blood bolus from secretory midgut epithelia, providing a 
second physical barrier that limits the infection by pathogens ingested during blood 
feeding (10). The PM is composed of 3-13% chitin microfibrils and is embedded with 
many identified (3) and un-identified proteins (11). Notably, when the ookinetes are 
mature 12 hours after the bloodmeal (9), the PM also becomes visible in the midgut 
                                                
1 Part of this work has been published on the Journal of Biological Chemistry. Zhang, G., Niu, G., 
Franca, C. M., et al., Anopheles Midgut FREP1 Mediates Plasmodium Invasion. J Biol Chem, 2015. 
290(27): p. 16490-501. http://www.jbc.org/cgi/doi/10.1074/jbc.M114.623165 
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lumen. In order to infect mosquitoes, the motile, banana-shaped ookinetes must 
sequentially attach to and penetrate the PM and the midgut epithelium (12). At present, 
the detailed molecular mechanisms involved in ookinete penetration of the PM are 
unclear. 
We recently identified a mosquito gene, fibrinogen-related protein 1 (FREP1), 
that is implicated in Plasmodium infection in mosquitoes (13). Genetic polymorphisms 
in FREP1 are significantly associated with P. falciparum infection intensity levels in 
wild An. gambiae populations from Kenya. The FREP1 protein is a member of the 
fibrinogen-related protein family (FREPs or FBNs) that contains a highly conserved C-
terminal interacting fibrinogen-like (FBN) domain. In vertebrates, fibrinogen molecules 
usually associate as hexamers and are comprised of two sets of disulfide-bridged α，β 
and γ chains that participate as a principal component of both cellular and fluid 
coagulation (14). In invertebrates, FREPs/FBNs are common pattern recognition 
receptors (PRR) (15,16) responsible mainly for initiating innate immune responses (17). 
For instance, tachylectin proteins in the horseshoe crab perform an effective host 
defense by recognizing bacterial lipopolysaccharides (18). Previous work examining the 
role and function of FREP/FBN family members in Anopheles mosquitoes has shown 
that two family members, FBN9 and FBN30, appear to restrict Plasmodium infection of 
midgut epithelial cells. Indeed, silencing the expression of either FBN9 or FBN30 in 
mosquitoes increased Plasmodium infection (13,19). Here, we report the role and 
function of a third FREP/FBN family member, FREP1, during P. falciparum infection 
of Anopheles mosquitoes. Our genetic and biochemical assays reveal that FREP1 
functions as a critical molecular anchor in the PM that facilitates Plasmodium invasion 
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and infection of mosquito midguts.  Furthermore, our results demonstrate that the highly 
conserved FBG is a functional domain of FREP1 that is responsible for the interaction 
between FREP1 protein and Plasmodium parasites. Collectively, our data reveal new 
insight into Plasmodium-Anopheles interactions and identify FREP1 as a promising 
transmission-blocking target. 
3.2 Material and Methods  
3.2.1 Rearing An. gambiae mosquitoes 
An. gambiae G3 strain was maintained at 27°C, 80% humidity with a 12-hour 
day-night cycle. Larvae were reared on ground KOI fish food supplements (0.1 mg per 
larvae per day). Adult mosquitoes were maintained with 8% sucrose and fed with mouse 
blood (mice were anesthetized with ketamine/xylazine) for egg production.  
3.2.2 Preparation of P. falciparum gametocytes and ookinetes  
P. falciparum parasites (NF54 strain from MR4) were added into O+ fresh human 
blood (4% red blood cells (RBC), 0.25-0.5% parasitemia). Cultures were maintained in 
6-well plates (Corning Incorporated Costar) with 5.0 ml complete RPMI-1640 medium 
supplemented with 10% heat-inactivated human AB-type serum (Interstate blood bank, 
Memphis) and 12.5 µg/ml hypoxanthine. The plates were maintained under 37 °C in a 
candle jar (20), and the medium was replaced daily until day 15-17. The parasitemia or 
gametocytemia was checked every other day by Giemsa staining of thin blood smears. 
To prepare ookinetes, the cultured P. falciparum cultures harboring stage V gametocytes 
were diluted 10-fold in complete RPMI-1640 (no sodium bicarbonate). The cultures 
were incubated at room temperature (RT) for 24 hours to simulate the formation of 
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zygotes and ookinetes (21). The culturing and infection experiments of P. falciparum 
were conducted in the biosafety level 2 lab at the University of Oklahoma. 
3.2.3 Generating anti-FREP1 polyclonal antibody 
FREP1 was cloned using PCR with primers shown in Table 2 from An. gambiae 
mosquito cDNA library that was generating by reversely transcribing from total RNA. 
The PCR product and pQE30 plasmid were digested with restriction enzymes Xma I and 
Hind III. After ligation and transformation into E. coli JM109, the positive plasmid 
verified by PCR was transformed into E. coli M15 strain. 1mM IPTG was used to 
induce gene expression in E. coli M15 strain. The expressed cells were lysed in buffer B 
(8 M Urea, 100mM NaH2PO4, 10mM Tris⋅Cl, pH 8.0). Since there was a 6xHis tag at 
the N-terminal of expressed protein, the recombinant FREP1 protein was purified by Ni-
NTA column using a standard protocol (22). SDS-PAGE and Coomassie Brilliant Blue 
R-250 staining confirmed the purity of recombinant FREP1 protein. The purified 
recombinant FREP1 was then used as an antigen to generate customized polyclonal 
antibody against FREP1 in rabbits (Thermo Fisher Scientific, Rockford, IL, USA).  
Rabbits were boosted three times in 2-week intervals, after which anti-FREP1 antibody 
in anti-serum was purified with the affinity chromatograph protein A-agarose and 
suspended in PBS.  
3.2.4 Expressing recombinant full FREP1, FBG and N-FREP1 protein in insect 
cells  
FREP1 complete coding sequence was obtained by PCR with primers shown in 
Table 3.1 from adult An. gambiae cDNA library. Primers specific to the N terminal 
FREP1 (amino acids 1-461) were used to amplify this fragment (see primers in Table 
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3.1).  FBG domain of FREP1 (amino acids 462-677) was cloned as described in chapter 
2. Full length FREP1, N- FREP1 and FBG domain were cloned into plasmid pIB/V5-
His (Life Tech, Grand Island, NY) to generate pIB-FREP1, N-FREP1, or FBG-His 
(encoding the respective protein with a 6xHis-tag), respectively. After amplified in E. 
coli DH5a, plasmids were purified with endotoxin-free plasmid preparation 
kits (Sigma-Aldrich, St. Louis, MO).  
The cabbage looper ovarian cell-derived High Five cells(23) was used to express 
all three recombinant proteins according to the manufacturers instructions (24). In brief, 
endotoxin-free recombinant pIB-FREP1 plasmids were mixed with Cellfectin® Reagent 
(1µl Cellfectin/µg plasmids, Invitrogen) in 5-6ml Express Five® SFM medium 
(Invitrogen, Grand Island, NY). The cells were cultured in 25cm2 cell culture flask 
(Greiner Bio-One, Monroe, NC) for 48 hours at 27°C. Medium and cells were separated 
by centrifugation at 300 g for 5 minutes. The proteins in medium were concentrated 
using Amicon® ULTRA-4 Centrifugal Filter Devices (Milipore, Billerica, MA) by 
centrifugation at 5,000 g for 10 minutes. All recombinatnt FREP1 proteins with 6xHis-
tag were purified using Ni-NTA column using a standard protocol (25). 
3.2.5 Gel Filtration Chromatography to determine the FREP1 protein size  
  Similar to the previous description (23), about 0.03-1mg purified high five-
expressed recombinant full FREP1 and N FREP1 protein in 0.1ml PBS was applied onto 
ÄktaTM Pure FPLC chromatography system (GE Healthcare) with superdex G-200 
increase column (60 cm in length, 0.5 cm in diameter) with flow rate controlled to 0.2 
ml/min. Superdex G-200 increase can separate proteins ranging from 5kDa to 600kDa. 
Fractions of approximately 0.1 ml were collected in an automated fraction collector. 
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UV280 absorbance was detected constantly, and ELISA was used to detect recombinant 
FREP1 protein in each fraction. Standard curve of molecule weight for the gel filtration 
column was obtained using a set of proteins with known molecular weights. 
3.2.6 Immunohistochemical (IHC) assay to determine protein distribution in 
mosquito tissues  
Midguts from 3-5 day-old naïve and bloodfed female mosquitoes were dissected 
in PBS with protease inhibitor (Thermo Scientific, Rockford, IL, USA). Tissues were 
embedded completely in optimal cutting temperature (OCT) compound and immediately 
frozen in liquid nitrogen. Frozen midguts were sectioned (8-10 µm) with a cryostat. The 
sections were mounted on super frost plus slides (positively charged), air dried for 30 
minutes at room temperature and fixed in 4% paraformaldehyde-PBS for 20 minutes and 
stored at -20ºC until use. Prior to staining, sections were re-hydrated in Tris-buffered 
saline (50 mM Tris, 150 mM NaCl, pH 7.6) with 0.05% tween-20 (TBST) for 10 
minutes. Sections were blocked with 1-3 drops of blocking solution (5% dry milk in 
TBST) for 30 minutes, and then incubated with 2.5µg/ml purified rabbit anti-FREP1 
antibodies in blocking solution for two hours. Control sections were incubated with 
blocking solution containing pre-immune rabbit antibodies. Samples were washed 3 
times for 5 minutes with TBST. Next 100 µl of 1:20,000 diluted goat anti-rabbit 
antibody conjugated with alkaline phosphatase (Sigma-Aldrich, St. Louis, MO) in 
blocking solution was incubated with each sample for 30 minutes at room temperature. 
Slides were then washed 3 times in TBST. Finally, the sections were developed with 100 
µl of BCIP/NBT Chromogenic Solution (Sigma-Aldrich; St. Louis, MO) for 10-20 
minutes, rinsed with water, and examined under a microscope at 4x and 40x 
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magnification. The Photoshop software (version CC 2014) was used to measure the gray 
values of selected areas. The darkness values were obtained by subtracting the measured 
gray values of a targeting area from background gray values. It is worth noting that we 
have validated this method of measuring darkness values by using different exposing 
time and using other software (such as Microsoft PowerPoint) to change the brightness 
and/or contrast of a photo. After the calculation, we always obtained similar values for a 
certain area. 
3.2.7 indirect immunofluorescence assays (IFA) to examine the binding between 
parasites and insect cell-expressed recombinant Full FREP1, FBG and N Terminal 
proteins. 
Standard IFA was performed as described previously (26). In brief, P. 
falciparum cultures were deposited on premium cover glass slip slides (Fisher 
Scientific) to make blood smears. Dry smears were fixed in 4% paraformaldehyde in 
PBS at RT for 30 minutes, and then sequentially incubated with 100 mM glycine in PBS 
for 20 minutes, 0.2% bovine serum albumin (BSA) in PBS for 90 minutes, high five 
cell-expressed FREP1 (10µg/ml) in 0.2% BSA-PBS for two hours, enhancer (Alexa 
Fluor ® 594 Goat Anti-Mouse SFX kit, Invitrogen) for 30 minutes, 5µg/ml anti-FREP1 
antibody in PBS containing 0.2% BSA for one hour, and 2µg/ml secondary antibody 
(Alexa Fluor ® 594 Goat Anti-rabbit Antibody, in PBS containg 0.2% BSA, Life 
Technologies Inc.) for 30 minutes. Between each incubation, the smears were washed 3 
times for 3 minutes in PBS containing 0.2% BSA. Cover slips were rinsed in distilled 
water for 20 seconds, and 50 µl vectashield mounting media (Vector Laboratories, 
Burlingame, CA) was added onto the cover slip and the cover slip was covered onto 
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slides. After incubating for at least 2 hours in dark, the cells were examined using Nikon 
Eclipse Ti-S fluorescence microscope. The fluoresence intensity was measured by the 
Photoshop software (version CC 2014). The actual fluoresence intensity of a target was 
calculated by substracting the mean background fluoresence intensity (gray values) from 
the mean target fluoresence intensity (gray values). At least three replicates were 
measured to calculate the mean values and standard deviations. 
3.2.8 Binding assays between FBG and PM.  
3-5-day old G3 An. gambiae mosquitoes were fed with mouse blood. The 
engorged mosquitoes were maintained in insectary (270C, 80% humidity) for 18 hrs. Ice-
anesthetized mosquitoes were then dissected to obtain midguts, and the blood bolus 
inside a midgut was removed by puncturing it. Blood fed-mosquito midguts and naïve 
mosquito midguts were incubated with 200µL of 0.1mg/ml BSA, full-length FREP1, N-
FREP1, and FBG separately for 2 hrs at RT. Ten midguts were used in each treatment. 
Three independent experimental replicates were performed. After incubation, midguts 
were homogenized with pestles in 300µL of 0.5% Tween-20 in PBS. Midgut lysate 
supernatants (50µL) were used to coat 96-well plates overnight at 4ºC. Since 
recombinant proteins of FREP1, FBG, N-FREP1 contain His-tag, the bound protein was 
probed with 50µL of mouse anti-His monoclonal antibody and developed as we 
mentioned above. 
3.3. Results 
3.3.1 Generating anti-FREP1 polyclonal antibody  
To understand the basic biochemical characteristics of FREP1 protein, we first 
examined its functional domains. According to our previous genome annotation (27), the 
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full length of FREP1 protein has 738 amino acids, including a 22-amino acid signal 
peptide at the N-terminal, three coiled-coil regions, and a conserved ~200-amino acid 
FBN domain at the C-terminal (Figure 3.1A). All six cysteine amino acid residuals are 
within FBN domain.   
To generate anti-FREP1 antibodies as an analytical tool, FREP1 coding region 
excluding the signal peptide region was cloned and expressed in E. coli M15 strain, and 
the expressed protein was purified by Ni-NTA column. The result indicated that the 
purity of E. coli-expressed recombinant FREP1 is >95% (Figure 3.1B, lane 3).  
Table 3-1. PCR primers. 
Primer name Primer sequence 
F FREP1 pQE30 5’-ACCCGGGCACTGCCCTGAACGGTGCAG-3’ 
R FREP1 pQE30 5'-GGCAAGCTTCGCGAACGTCGGCACAGTC-3' 
F FREP1 pIB/V5-
His 
5’-TCAAAGCTTCACCATGGTGAATTCATTCGTGTCG-3’ 
R FREP1 pIB/V5-
His 
5’-ACTCTAGAGCGAACGTCGGCACAGTCGTG-3’ 
F FBG FREP1 
pIB/V5-His 
5’-TCAGAATTCCACCATGGAGTCGATCATCAAC-3’ 
R FBG FREP1 
pIB/V5-His 
5’-ACTCTAGACTCGGCCGGCGGGCAATCATCATGT-3’ 
F N FREP1 
pIB/V5-His 
5’-
TCAAGCTTCACCATGGTGAATTCATTCGTGTCGGTA-3’ 
R N FREP1 
pIB/V5-His 
5’-ACTCTAGACTGTACTCGTGCTCGACCGACTC-3’ 
Italic and underlined sequences denote restriction recognition sites. The bold sequence is 
Kozak consensus sequences. The primers were synthesized through Integrated DNA 
Technologies Inc. 
 
 
Injecting the purified FREP1 protein into rabbits generated the anti-FREP1 anti-
serum. The antibodies were purified using affinity chromatography protein A/G-agarose. 
Western blot result showed that the purified polyclonal rabbit anti-FREP1 antibody can 
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recognize recombinant FREP1 specifically (Figure 3.1C). The purified anti-FREP1 
antibodies were used in this study. 
3.3.2 Recombinant FREP1 protein is secreted from insect cells into culture 
medium, and form tetramers 
We examined cellular FREP1 expression patterns in vitro. We cloned the full-
length FREP1 into the plasmid pIB/V5-His under the baculovirus OplE2 promoter and 
expressed its product in High Five insect cells. The results showed that FREP1 protein 
was exclusively detected in the cell culture supernatant, and no FREP1 protein was 
detected in the cell pellet (Fig. 3.1D), indicating FREP1 is a secreted protein. Notably, 
only one band was detected by anti-FREP1 antibody in the western blot membrane. 
Next, we determined whether FREP1 protein assumes distinct quaternary 
structures. On SDS-PAGE gel, the purified insect cell-expressed recombinant FREP1 
protein showed the same molecular weight under both reducing (with 2-
mercaptoethanol) and non-reducing conditions (Fig. 3.1E), indicating that insect cell-
expressed recombinant FREP1 protein exists as either monomers or multimers that 
associate via non- covalent bonds. 
The molecular weight of insect-expressed recombinant FREP1 protein (~95kDa, 
Fig. 3-1E) is greater than the calculated molecular weight (83.5kDa), suggesting post-
translational modification of secreted FREP1 protein. Size exclusion chromatography 
was then utilized to separate recombinant FREP1 protein and protein complexes. Based 
on the gel-filtration standard curve, the major recombinant FREP1 peak appeared to be 
between 308kDa and 409kDa (Fig. 3-1F). Because the unit molecular weight of 
recombinant FREP1 is about 95kDa, our data support that the majority of FREP1 protein 
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exists as tetramers (~380kDa). In addition monomers, dimers and trimers also exist (Fig. 
3-1F).  
3.3.3 The FREP1 N-terminal domain forms oligomers  
Sequence alignments revealed that the orthologs of N-terminal of FREP1 
between amino acids 23 and 462 are highly variable. To understand the function of this 
region, we cloned this fragment into pIB/V5-His and expressed it in High Five cells. 
This recombinant protein (named N-FREP1 in this paper, 52.9kD) was secreted into 
medium and purified with Ni-NTA column. SDS-PAGE showed one enriched band, 
indicating the purified recombinant N-FREP1 did not contain any major contaminations 
(Fig. 3.2A). Furthermore, a size exclusion chromatography using Superdex G200 
increase column was applied to determine molecular weight of native N-FREP1. Results 
(Fig 3.2B) indicate that the majority of N-FREP1 recombinant protein forms tetramers, 
which is consistent to our published molecular model of FREP1 as a tetramer. 
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Figure 3-1. FREP1 is secreted from insect cells and forms tetramers. 
FREP1 is secreted from insect cells and forms tetramers. A: FREP1 protein has a N-
terminal signal peptide, three coiled coils, and a C-terminal FBN domain. B: The 
FREP1 gene was cloned and expressed in E. coli M15 strain. On 12% SDS-PAGE 
stained with Coomassie Brilliant Blue, lane 1: before induced; lane 2: after induced by 
IPTG); lane 3: the expressed recombinant FREP1 was purified with Ni-NTA column. C: 
Western blot using anti-FREP1 antibody to detect specifically recombinant FREP1 
protein. D: SDS-PAGE (left) and western blot (right) showing that the recombinant 
FREP1 protein is secreted from High Five cells into culture medium. “S” and “P” 
represent supernatant and cell pellet respectively. Only one band was detected by anti-
FREP1 antibody.  E: The purified recombinant FREP1 expressed in High Five insect 
cells on reducing (lane 1) and non-reducing (lane 2) 12% SDS-PAGE, stained with 
Coomassie Brilliant Blue. F: The UV280 absorbance profile of the purified insect cell-
expressed recombinant FREP1 in PBS using Superdex G-200 gel filtration 
chromatography. 
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3.3.4 FREP1 protein localizes to the peritrophic matrix in mosquito midguts after 
blood feeding 
Published microarray-based gene expression data (28,29) support that FREP1 
has higher expression in mosquito midguts, compared to other tissues, and FREP1 is up 
regulated by bloodmeal. We then, used the generated polyclonal anti-FREP1 antibodies 
in IHC assays to determine the localization of endogenous FREP1 in mosquito midguts.  
To determine whether anti-FREP1 can specifically recognize FREP1 in 
mosquitoes, we dissected midguts from bloodfed mosquitoes (18 hours after bloodmeal) 
and naïve mosquitoes. The blood in bloodfed mosquito midguts was manually removed. 
On SDS-PAGE, the protein composition of bloodfed mosquito midguts was 
distinct from naïve mosquitoes (Figure 3-3A), which is consistent to previous reports of 
blood-regulation of mosquito gene expression (13). The western blot detected only one 
band in homogenized bloodfed mosquito midguts, and no band was detected in naïve 
mosquito midguts (Figure 3-3B). These results are consistent to microarray data 
showing that blood up-regulates FREP1 expression. These data also further confirm the 
specificity of rabbit polyclonal anti-FREP1 antibody for endogenous FREP1 protein 
expressed in mosquitoes. 
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Figure 3-2. The most abundant form of native N-FREP1 is tetramer. 
A: SDS-PAGE of purified recombinant N-FREP1 (10µL). B: Size exclusion 
chromatography (SEC) of insect cell expressed recombinant N-FREP1purified by Ni-
NTA affinity chromatography. Approximately 8 nmoles of the sample was injected into 
a 500µL loading loop and then run over a Superdex 200 increase column using 50mM 
NaH2PO4 pH 8.0, 300mM NaCl at a flow rate of 0.5ml/min. A fixed wavelength UV 
monitor monitored the elutions. Elution time corresponding to the oligomers size was 
estimated from N-FREP1 molecular weight (52.9 kDa). 
 
IHC assays were performed to localize FREP1 proteins in mosquitoes. 
Comparisons between the negative control IHC sections (Figure 3-3C, pre-immune 
antibody) and the experimentally stained sections (Figure 3-3D, anti-FREP1 antibody) 
of naïve mosquito midguts did not show any significance (Figure 3-3E). However, 12 
hours post bloodmeal, the FREP1 signal (purple color) in experimental sections (Figure 
3.2G) is significantly more intense (P<0.01, Figure 3-3H) than that in control sections 
(Figure 3-3F), indicating that the FREP1 protein was up-expressed in mosquito midguts 
after bloodmeal. These data are also consistent with the western blot result (Figure 3-3B) 
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and published microarray-based expression data showing up-regulation of FREP1 
mRNA expression in mosquitoes three hours after bloodmeal feeding (13). Furthermore, 
two portions of stained midgut sections (rectangles in Figure 3-3F and G) were 
magnified 40X to show a more detailed structure (Figure. 3-3I and Figure. 3-3J, 
respectively). Strikingly, we found that the majority of FREP1 protein was localized in 
the mosquito PM that resides within the midgut lumen. Consistent staining patterns and 
FREP1 localization were observed in more than 3 independent experiments, and the 
statistical analysis of darkness values between control and experiment groups confirms 
that significantly more FREP1 protein was detected after bloodmeal (Figure 3-3H and 3-
3K). Together, the data from the microarray analyses and our new western blot and IHC 
studies consistently show that FREP1 gene is up-regulated after blood feeding and that 
FREP1 protein is secreted into mosquito midgut lumen and associated with the PM.  
3.3.5 FBG binds mosquito midgut peritrophic matrix  
To verify FREP1 protein association with the PM, we analyzed the interactions 
between mosquito midguts and recombinant full-length FREP1, FBG and N-FREP1 
proteins to determine which domain is responsible for this interaction. Since PM forms 
only after a bloodmeal, blood fed-mosquito midguts and naïve mosquito midguts were 
incubated with BSA, recombinant FREP1, N-FREP1, and FBG separately. Ten midguts 
were used in each treatment. Three independent experimental replicates were performed. 
BSA and FREP1 are negative and positive control respectively. Since naïve mosquito 
midguts do not contain PM, they are used as negative controls as well. After  
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Figure 3-3. FREP1 localizes in the mosquito midgut peritrophic matrix. 
FREP1 protein localizes to the mosquito midgut peritrophic matrix. A: Midgut proteins 
from bloodfed and naïve mosquitoes were fractionated on 10% SDS-PAGE and stained 
with Coomassie Brilliant Blue. B: Midgut proteins of bloodfed and naïve mosquitoes 
were fractionated on 10% SDS-PAGE, transferred to membranes and probed with anti-
FREP1 antibody.  Western blot data show anti-FREP1 antibody specifically recognized 
FREP1 in bloodfed mosquito midguts. C, F, and I: Negative control of naïve and blood 
fed An. gambiae midgut in which purified pre-immune rabbit antibody was used to 
detect FREP1 protein. D, G, and J: Experimental groups of naïve and blood fed An. 
gambiae midguts in which anti-FREP1 rabbit antibody was used to detect FREP1 
protein; I and J are the magnification of areas on F and G (highlighted by rectangles) 
respectively. Locations of the midgut epithelium, the peritrophic matrix, the FREP1 
protein and the blood bolus are annotated on the images. Summary data in E, H, and K 
show the statistical difference of darkness values between negative controls and 
experimental groups in three experimental replicates. 
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incubation, midguts and their binding proteins were homogenized, and extracts were 
used to coat an ELISA plate. The bound recombinant FREP1, N-FREP1, and FBG were 
probed with anti-His monoclonal antibody. After development with ELISA reagents, 
FREP1- and FBG- incubated with blood-fed mosquito midguts exhibited significantly 
(p<0.005) higher signal than BSA-incubated midguts. There is no significant (p>0.4) 
difference between N-FREP1 incubated midguts and negative controls (Fig 3.4). These 
results support FBG binding to PM. 
3.3.6 FBG binds sexual stage ookinetes 
We determined the molecular relationship between FBG and parasites. We 
previously showed that FREP1 binds to P. falciparum (NF54) sexual stage gametocytes 
and ookinetes [30]. In this study, we examined the capacity for the purified FBG domain 
of FREP1 to bind P. falciparum parasites, gametocytes and ookinetes in particular. 
 
Figure 3-4. FBG binds to mosquito peritrophic membrane. 
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Non-infected human red blood cells (RBC), P. falciparum gametocytes, and ookinetes 
were fixed on cover slips (non-permeabilized). After incubation with insect cell-
expressed FBG recombinant protein, we detected parasite bound FBG protein by 
indirect immunofluorescence assays. The results showed that FREP1 FBG bound 
gametocytes (Fig. 3-5, row B), early stage ookinetes (just merged with a sharp tail, Fig. 
3-5, row C) and ookinetes (Fig. 3-5, row D). The binding signals were not observed 
when non-infected human RBC were assayed (Fig. 3-5, row A), confirming that FBG 
does not bind healthy human RBCs. Additional negative controls included incubation of 
P. falciparum gametocytes with an irrelevant protein (chloramphenicol 
acetyltransferase, CAT) expressed in the same system. As shown in Fig. 3-5, row E, 
there were no binding signals in control groups. Therefore, FBG fragment is a functional 
domain of FREP1 that is responsible for the interaction between FREP1 protein and 
Plasmodium parasites.  
3.4 Discussion  
We previously reported that the polymorphisms within FREP1 were strongly 
associated with reduced P. falciparum infection intensity (13). Our current work aimed 
to investigate the molecular mechanisms and functions of FREP1 protein during 
infection of mosquitoes by the human malaria pathogen P. falciparum.  First, we 
demonstrated that FREP1 protein is expressed in the mosquito midgut PM and exerts its 
effects on Plasmodium infection in the PM. It is well known that PM formation occurs 
ubiquitously in the midguts of hematophagous insects and serves as an important 
physical barrier to resist or prevent invasion by pathogens in blood(11). Previous studies 
showed that the FREP1 gene expression is up-regulated by bloodmeal (29).  
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Here we showed that FREP1 protein is secreted into the mosquito midgut lumen 
after a bloodmeal and is associated with the PM. It is reported that FBN domains in 
FREPs can recognize N- acetylglucosamine of chitin (31,32), other carbohydrates and 
their derivatives (17,32), and our data confirmed that FREP1 protein binds PM. We 
speculate that the FREP1 protein is a structural and functional protein in PM that 
interacts with chitin and other carbohydrates via the FBN domain of FREP1. This 
interaction keeps FREP1 proteins closely associated with the PM following bloodmeal 
feeding. 
Second, our data supports the quaternary structure of FREP1 to be tetramers. 
Invertebrate FREP/FBN family members tend to multimerize in order to exert their 
physiological functions (33). For example, the An. gambiae mosquito FBN9 protein 
forms dimers that interact with Gram-positive and Gram-negative bacteria (19). 
Moreover, the functional forms of horseshoe crab TL-5A and TL-5B proteins form 
propeller-like structures with each blade corresponding to a disulfide-linked dimer (34).  
Similarly, our results showed that FREP1 forms tetramers through hydrophobic forces 
instead of disulfide-bonds since non-reducing SDS-PAGE showed that insect cell-
expressed FREP1 are a monomer and size exclusion chromatography showed that 
FREP1 forms a tetramer. Coiled-coil motifs in proteins have been reported to mediate 
protein homodimer complexes (35) and tetramer complex formation (36). Consistent 
with this, the elution profile of N-FREP1 accounts for the tetrameric form of FREP1. 
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Figure 3-5. Insect cell-expressed recombinant FREP1 FBG protein interaction with 
Plasmodium falciparum was detected by indirect immunofluorescence assay (IFA). 
The first and second columns depict cell nuclei stained with DAPI and binding FBG 
proteins, respectively. Merging column one and two generated the third column, 
showing the co-localization of P. falciparum (nuclei) and FBG protein binding. The 4th 
column shows the bright views of the cells. Row A: FBG does not bind to un-infected 
RBC. Row B: FBG binds to P. falciparum gametocytes. Row C, D: FBG binds to P. 
falciparum ookinetes. Row E: An irrelevant control protein (CAT) does not bind P. 
falciparum parasites. 
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Third, IFA assays demonstrated that the FREP1 protein interacts with sexual 
stage (gametocytes) and mosquito midgut invasion stage (ookinetes) P. falciparum 
parasites. The putative parasite-expressed FREP1-binding partners are expected to 
localize on the cell surface of the parasites (including asexual stages, sexual stages, and 
ookinetes), because non-permeabilized approaches were used in IFA to detect the 
interaction between FREP1 protein and parasites. We discovered that FBG domain in 
FREP1 binds Plasmodium gametocytes and ookinetes. Since FREPs were proposed to 
act as pattern recognition molecules (19), the C-terminal FBN domain within FREP1 is 
likely responsible for mediating interactions between FREP1 proteins and Plasmodium 
parasites. Since FREP1 is localized in the mosquito midgut PM, our data support our 
prediction that FBG domain interacts with PM as well. 
In summary, we discovered that Anopheles gambiae FREP1 is a secreted protein 
that forms oligomers (tetramer) via the coiled-coil regions in the N terminal, and it 
localizes within the peritrophic matrix of mosquitoes. We propose that the functional 
FBG domain of FREP1 has dual role in assisting Plasmodium invasion of mosquito 
midgut by directly binding to parasite and the PM, facilitating ookinete penetration of 
the midgut epithelia. Thus, FREP1 constitutes an ideal mosquito antigen target for 
malaria transmission-blocking vaccines.  
3.5 Acknowledgment  
This dissertation reports data obtained in the University of Oklahoma Protein 
Production Core, which is supported by an Institutional Development Award (IDeA) 
from the National Institute of General Medicine Sciences of the National Institutes of 
Health under the grant number P20GM103640.   
69 
3.6 References 
1. Christophides, G. K., and Crisanti, A. (2013) Vector and vector-borne disease 
research: need for coherence, vision and strategic planning. Pathogens and global 
health 107, 385-386 
 
2. Zhao, B., Kokoza, V. A., Saha, T. T., Wang, S., Roy, S., and Raikhel, A. S. (2014) 
Regulation of the gut-specific carboxypeptidase: A study using the binary Gal4/UAS 
system in the mosquito Aedes aegypti. Insect biochemistry and molecular biology 
54C, 1-10 
 
3. Dinglasan, R. R., Devenport, M., Florens, L., Johnson, J. R., McHugh, C. A., 
Donnelly-Doman, M., Carucci, D. J., Yates, J. R., 3rd, and Jacobs-Lorena, M. (2009) 
The Anopheles gambiae adult midgut peritrophic matrix proteome. Insect 
biochemistry and molecular biology 39, 125-134 
 
4. Abraham, E. G., and Jacobs-Lorena, M. (2004) Mosquito midgut barriers to malaria 
parasite development. Insect biochemistry and molecular biology 34, 667-671 
 
5. Pumpuni, C. B., Demaio, J., Kent, M., Davis, J. R., and Beier, J. C. (1996) Bacterial 
population dynamics in three anopheline species: the impact on Plasmodium 
sporogonic development. The American journal of tropical medicine and hygiene 54, 
214-218 
 
6. Gonzalez-Ceron, L., Santillan, F., Rodriguez, M. H., Mendez, D., and Hernandez-
Avila, J. E. (2003) Bacteria in midguts of field-collected Anopheles albimanus block 
Plasmodium vivax sporogonic development. Journal of medical entomology 40, 
371-374 
 
7. Mead, E. A., Li, M., Tu, Z., and Zhu, J. (2012) Translational regulation of 
Anopheles gambiae mRNAs in the midgut during Plasmodium falciparum infection. 
BMC genomics 13, 366 
 
8. Christophides, G. K., Vlachou, D., and Kafatos, F. C. (2004) Comparative and 
functional genomics of the innate immune system in the malaria vector Anopheles 
gambiae. Immunological reviews 198, 127-148 
 
9. Billingsley, P. F. (1990) The Midgut Ultrastructure of Hematophagous Insects. Annu 
Rev Entomol 35, 219-248 
 
10. Shao, L., Devenport, M., and Jacobs-Lorena, M. (2001) The peritrophic matrix of 
hematophagous insects. Archives of insect biochemistry and physiology 47, 119-125 
 
11. Toprak, U., Baldwin, D., Erlandson, M., Gillott, C., and Hegedus, D. D. (2010) 
Insect intestinal mucins and serine proteases associated with the peritrophic matrix 
70 
from feeding, starved and moulting Mamestra configurata larvae. Insect molecular 
biology 19, 163-175 
 
12. Sinden, R. E., and Billingsley, P. F. (2001) Plasmodium invasion of mosquito cells: 
hawk or dove? Trends in parasitology 17, 209-212 
 
13. Li, J., Wang, X., Zhang, G., Githure, J., Yan, G., and James, A. A. (2013) Genome-
block expression-assisted association studies discover malaria resistance genes in 
Anopheles gambiae. Proceedings of the National Academy of Sciences of the United 
States of America 110, 20675-20680 
 
14. Mosesson, M. W. (2005) Fibrinogen and fibrin structure and functions. Journal of 
thrombosis and haemostasis : JTH 3, 1894-1904 
 
15. Zhang, H., Wang, L., Song, L., Song, X., Wang, B., Mu, C., and Zhang, Y. (2009) A 
fibrinogen-related protein from bay scallop Argopecten irradians involved in innate 
immunity as pattern recognition receptor. Fish & shellfish immunology 26, 56-64 
 
16. Fan, C., Zhang, S., Li, L., and Chao, Y. (2008) Fibrinogen-related protein from 
amphioxus Branchiostoma belcheri is a multivalent pattern recognition receptor with 
a bacteriolytic activity. Molecular immunology 45, 3338-3346 
 
17. Wang, X., Zhao, Q., and Christensen, B. M. (2005) Identification and 
characterization of the fibrinogen-like domain of fibrinogen-related proteins in the 
mosquito, Anopheles gambiae, and the fruitfly, Drosophila melanogaster, genomes. 
BMC genomics 6, 114 
 
18. Kawabata, S., and Iwanaga, S. (1999) Role of lectins in the innate immunity of 
horseshoe crab. Developmental and comparative immunology 23, 391-400 
 
19. Dong, Y., and Dimopoulos, G. (2009) Anopheles fibrinogen-related proteins provide 
expanded pattern recognition capacity against bacteria and malaria parasites. The 
Journal of biological chemistry 284, 9835-9844 
 
20. Jensen, J. B., and Trager, W. (1977) Plasmodium falciparum in culture: use of 
outdated erthrocytes and description of the candle jar method. The Journal of 
parasitology 63, 883-886 
 
21. Beetsma, A. L., van de Wiel, T. J., Sauerwein, R. W., and Eling, W. M. (1998) 
Plasmodium berghei ANKA: purification of large numbers of infectious 
gametocytes. Exp Parasitol 88, 69-72 
 
22. Wickham, T. J., Davis, T., Granados, R. R., Shuler, M. L., and Wood, H. A. (1992) 
Screening of insect cell lines for the production of recombinant proteins and 
infectious virus in the baculovirus expression system. Biotechnology progress 8, 
391-396 
71 
23. Invitrogen. (2008) InsectSelect BSD system: For stable expression of heterologous 
proteins in lepidopteran insect cell lines using pIB/V5-His.  (technologies, L. ed., 
Life technologies 
 
24. Duong-Ly, K. C., and Gabelli, S. B. (2014) Gel filtration chromatography (size 
exclusion chromatography) of proteins. Methods in enzymology 541, 105-114 
 
25. QIAGEN. (2003) The QIAexpressionist: A handbood for high-level expression and 
purification of 6XHis-tagged proteins, QIAGEN, QIAGEN 
 
26. Korochkina, S., Barreau, C., Pradel, G., Jeffery, E., Li, J., Natarajan, R., 
Shabanowitz, J., Hunt, D., Frevert, U., and Vernick, K. D. (2006) A mosquito-
specific protein family includes candidate receptors for malaria sporozoite invasion 
of salivary glands. Cellular microbiology 8, 163-175 
 
27. Li, J., Ribeiro, J. M., and Yan, G. (2010) Allelic gene structure variations in 
Anopheles gambiae mosquitoes. PLoS One 5, e10699 
 
28. Marinotti, O., Calvo, E., Nguyen, Q. K., Dissanayake, S., Ribeiro, J. M., and James, 
A. A. (2006) Genome-wide analysis of gene expression in adult Anopheles gambiae. 
Insect molecular biology 15, 1-12 
 
29. Baker, D. A., Nolan, T., Fischer, B., Pinder, A., Crisanti, A., and Russell, S. (2011) 
A comprehensive gene expression atlas of sex- and tissue-specificity in the malaria 
vector, Anopheles gambiae. BMC genomics 12, 296 
 
30. Zhang, G., et al., Anopheles Midgut FREP1 Mediates Plasmodium Invasion. J Biol 
Chem, 2015. 290(27): p. 16490-501. 
 
31. Angrisano, F., Riglar, D. T., Sturm, A., Volz, J. C., Delves, M. J., Zuccala, E. S., 
Turnbull, L.,Dekiwadia, C., Olshina, M. A., Marapana, D. S., Wong, W., Mollard, 
V., Bradin, C. H., Tonkin, C. J.,Gunning, P. W., Ralph, S. A., Whitchurch, C. B., 
Sinden, R. E., Cowman, A. F., McFadden, G. I., and Baum, J. (2012) Spatial 
localisation of actin filaments across developmental stages of the malaria parasite. 
PLoS One 7, e32188 
 
32. Sugimoto, R., Yae, Y., Akaiwa, M., Kitajima, S., Shibata, Y., Sato, H., Hirata, J., 
Okochi, K., Izuhara, K., and Hamasaki, N. (1998) Cloning and characterization of 
the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. The Journal 
of biological chemistry 273, 20721-20727 
 
33. Garlatti, V., Belloy, N., Martin, L., Lacroix, M., Matsushita, M., Endo, Y., Fujita, T., 
Fontecilla-Camps, J. C., Arlaud, G. J., Thielens, N. M., and Gaboriaud, C. (2007) 
Structural insights into the innate immune recognition specificities of L- and H-
ficolins. The EMBO journal 26, 623-633 
72 
34. Hanington, P. C., and Zhang, S. M. (2011) The primary role of fibrinogen-related 
proteins in invertebrates is defense, not coagulation. Journal of innate immunity 3, 
17-27 
 
35. Gokudan, S., Muta, T., Tsuda, R., Koori, K., Kawahara, T., Seki, N., Mizunoe, Y., 
Wai, S. N., Iwanaga, S., and Kawabata, S. (1999) Horseshoe crab acetyl group-
recognizing lectins involved in innate immunity are structurally related to 
fibrinogen. Proc Natl Acad Sci U S A 96, 10086-10091 
 
36. Qiu, J. J., Chu, H., Lu, X., Jiang, X., and Dong, S. (2011) The reduced and altered 
activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil 
domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic 
leukemia. Oncogene 30, 967-977 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
Chapter 4: Fibrinogen domain of FREP1 is a broad spectrum malaria 
transmission-blocking vaccine antigen 
 
4.1 Introduction  
Malaria death rates have dropped by 47% between 2000 and 2013 globally, and 
by 54% in Africa due to applications of several anti-malaria strategies including anti-
malaria drugs, insecticide-treated nets, and indoor insecticide spraying. Despite these 
efforts, more than 587,000 still died and 90% of these deaths occurred in Sub-Saharan 
Africa in 2014 [1]. The rapid spread of drug-resistant malaria parasites and insecticide-
resistant mosquitoes along with the absence of efficient vaccines against malaria present 
major challenges for malaria control. Therefore, new approaches are urgently needed. 
Transmission blocking vaccines (TBVs) have been recently considered as a promising 
measure to combat malaria. TBVs are designed to block parasite development in the 
mosquito midgut upon ingestion with the human antibodies against antigens from either 
parasites or mosquitoes.  
Human malaria is caused by Plasmodium falciparum, P. vivax, P. ovale, P. 
malariae and P.  knowlesi, of which P. falciparum and P. vivax are responsible for 
~99% of malaria cases. Since only gametocytes can infect mosquitoes, antigens on the 
surface of gametocytes and/or ookinetes such as Pfs25, Pfs48/45 and Pfs230 have been 
evaluated as TBV candidates in preclinical studies [2-4]. Among them, Pfs25 and its 
ortholog Pvs25 from P. vivax are the only candidates to progress to clinical trials. Pfs25 
is a 25-kDa sexual stage specific protein expressed on the surface of the parasite during 
several sexual developmental stages including gamete, zygote and ookinete [5].  Clinical 
74 
trials of Pfs25 only showed moderate levels of transmission-blocking activity [6], 
underscoring the need to identify additional and novel antigens for TBV development. 
About 30 anopheline mosquito species transmit malaria[7]. The major malaria 
vectors in Africa are Anopheles gambiae, An. arabiensis and An. funestus. In Asia, the 
most important species are An. stephensi and An. dirus. In South America, An. minimus, 
An. albimanus and An. darlingi are responsible for malaria transmission [2, 8, 9].  To 
successfully transmit malaria, Plasmodium parasites must complete a complex 
developmental cycle in both human and mosquito hosts. Thus, mosquito midgut 
molecules that facilitate ookinete invasion are likely to serve as ideal targets for TBVs. 
Previous studies showed that polyclonal antibodies against mosquito alanyl 
aminopeptidase 1 (APN1) or carboxypeptidases B (CPB) [2, 10] inhibited 73% and 51% 
parasite development in mosquito midguts respectively using P. berghei-mouse 
infection system.  
Since human malaria is caused by several Plasmodium species and transmitted 
by numerous Anopheles species, and many endemic areas have both P. falciparum and 
P. vivax malaria cases and transmitted by several different Anopheles species, an ideal 
TBV antigen would effectively block malaria transmission of multiple parasite species 
to multiple mosquito species. We recently reported that FREP1 plays a pivotal role in 
ookinete invasion of the mosquito midgut [11]. FREP1 is a tetramer that localizes within 
the peritrophic matrix, and facilitates Plasmodium invasion through direct binding to 
gametocytes and ookinetes. In this study, we demonstrate that a highly conserved FBG 
domain within FREP1 is a broad-spectrum TBV antigen that blocks transmission of 
multiple Plasmodium species to multiple Anopheles species, which supports FREP1-
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mediated Plasmodium invasion to mosquitoes as a conserved pathway. In particular, in 
vivo mouse model demonstrates FBG as a vaccine that blocks >75% transmission of P. 
berghei, better than reported mosquito TBV antigens (APN1, CBP) [2, 10]. It is worth 
noting that only three mosquito proteins have been identified suitable for malaria TBV 
antigens. Membrane feeding assays showed anti-FBG serum blocked >81% transmission 
of P. falciparum, which meets the target product profile (TPP) set as guideline for 
malaria TBVs for clinical trials (>80%) [12]. 
4.2 Material and Methods  
4.2.1 Ethics Statement  
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health 
(NIH). Mice were used according to approved protocols (R15-012) by the University of 
Oklahoma Institutional Animal Care and Use Committee (A3240-01). The P. vivax 
infected patients blood was used to examine the efficacy of antibodies. We followed the 
NIH Human Subjects Policies and Guidance. The Ethical Review Committee of the 
Faculty of Tropical Medicine, Mahidol University approved P. vivax infection protocols 
(MUTM 2011-040-05). 
4.2.2 Mosquito and P. falciparum maintenance 
An. gambiae G3 strain and An. dirus were reared in an insectary room 
maintained at 27°C, 80% humidity with a 12-hr day/night cycle. Larvae were fed with 
ground fish food (KOI, 0.1mg per larvae per day). Adult mosquitoes were maintained on 
8% (w/v) sucrose and fed with mouse blood for egg production. P. falciparum parasites 
(NF54 strain from MR4, Manassas, VA) were maintained in RPMI-1640 medium (Life 
76 
Tech, Grand Island, NY) supplemented with 10% heat-inactivated (56°C for 45 min) 
human AB+ serum (Interstate blood bank, Memphis, TN), 12.5 µg/mL hypoxanthine 
and 4% haematocrit (O+ human blood) in a candle jar at 37°C as described previously 
[11].  
4.2.3 In vitro transmission-blocking assay of P. berghei infection in An. gambiae 
with anti-FREP1 antibodies 
 P. berghei (ANKA GFPcon strain) infected mouse blood was precipitated by 
centrifugation (2000xg for 3 minutes). The blood pellet was then mixed with an equal 
volume of anti-serum. The standard membrane-feeding assay (SMFA) [15] was 
conducted using 3-days old female naïve mosquitoes. After feeding for 20 minutes, the 
engorged mosquitoes were maintained on 8% sugar (w/v) at 19°C. Seven days after 
infection, mosquitoes were dissected and the midguts were stained with 0.2% 
mercurochrome and examined using light microscopy to count the number of oocysts. 
Data were analyzed with nonparametric Wilcoxon test implemented in software R-
project. 
4.2.4 In vitro transmission-blocking assay of P. vivax infection in An. dirus 
mosquitoes with anti-FREP1 antibodies  
Field isolates of P. vivax were collected from patients attending malaria clinics in 
Ubonratchanthani province, Thailand. Within 10 hours after collecting blood, aliquots of 
350 µl of infected blood were prepared. The infected blood was centrifuged at 1,500 xg 
for 5 min and plasma was removed. Packed blood was washed once with RPMI-1640 
incomplete medium. The antiserum was mixed with P. vivax infected packed blood at 
1:1 ratio (v/v). The suspension was incubated at room temperature for 15 minutes before 
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being fed to 100 female An. dirus (age 5-7 days) per treatment for 30 minutes using 
membrane-feeding device. The packed infected blood mixed with naïve human AB 
serum at 1:1 ratio (v/v) was used as a control. Engorged mosquitoes were kept on 10% 
sugar solution. The number of oocysts in mosquito midguts was determined under a 
microscope at day 7-post bloodmeal. 
4.2.5 Gene cloning, protein expression, and purification 
 The full length coding sequence of An. gambiae FREP1 was amplified as 
described previously [11]. The FREP1 FBG fragment was amplified with the gene 
specific primers (5’-ACGCATGCCACGAGTACGAGTCGATC-3’, 5’-
TGCAAGCTTGTACTCGTGCTCGACCGACTC-3’), PCR fragment was cloned into 
pQE30 vector and expressed E. coli strain M15[pREP4] (Qiagen, Valencia, CA) with 
0.5 mM isopropyl-1-thio-β-D-galactopyranoside at room temperature. The recombinant 
protein was purified on a Ni-nitrilotriacetic acid column (Qiagen) and eluted with Buffer 
D (20 mM Sodium Phosphate, 500 mM NaCl, 8M Urea, PH4.0). The eluted fractions 
were analyzed on 12% SDS-PAGE gel followed by Coomassie blue staining to examine 
the purity. All fractions containing protein were then combined and protein 
concentration was determined using the Bradford protein assay [16].  
4.2.6 Expression of recombinant FREP1 protein in insect cell High Five cells 
 As described previously [11], the full-length FREP1 was cloned into plasmid 
pIB/V5-His (Life Technologies, Carlsbad, CA). After being amplified in E. coli DH5α, 
plasmids were purified using GenElute Endotoxin-free plasmid preparation kits (Sigma-
Aldrich, St. Lois, MO). The purified recombinant plasmids pIB-FREP1 and pIB-
chloramphenicol acetyltransferase (CAT) (as a control) were transformed into 40-60% 
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confluent cabbage looper ovarian cell-derived High Five cells. Cellfectin® Reagent 
(Invitrogen, Carlsbad, CA) was mixed with each individual plasmids (1µl Cellfectin/µg 
plasmids) in 5-6 ml Express Five® SFM medium (Invitrogen) to transfect into cells. 
After 5 generations of dilution, the cells that stably expressed the recombinant protein 
were cultured in 25cm2 CELLSTAR® cell culture flask (Greiner Bio-One, Monroe, NC) 
for 48 hrs at 27°C. The secreted FREP1 protein in medium was purified using Ni-NTA 
column and dissolved in PBS for use.  
4.2.7 Immunizations of mice with FREP1 and FBG 
 Five Hsd:ND4 female (20-25g; 7 to 8 weeks old) mice were primed via 
subcutaneous (s.c.) injection and boosted two times at 3-week intervals via (s.c.) 
injection with 20µg of FREP1 per mouse in 200 µL phosphate buffer saline (PBS) 
adsorbed (1:1) in Alhydrogel adjuvant. The control mice were primed or boosted with 
PBS only and emulsified (1:1) with Alhydrogel. Similarly, five mice were injected (s.c.) 
with FBG protein under the same regime for optimal-prime boosting with 20µg of the 
purified recombinant protein in 0.5X buffer D, with control group comprised of five 
mice injected with 0.5X buffer D emulsified in alhydrogel instead. Serum was collected 
from each mouse prior to each priming and boosting immunization. Animals were 
sacrificed following in vivo feeding assays, and blood was collected via orbital sinus 
[17]. Blood samples were centrifuged at 2,000x g, for 20 minutes at 4ºC for serum 
separation. 
4.2.8 In vivo transmission-blocking assay with the immunized mice 
  Mice were immunized with the same regime for optimal-prime boosting as 
described above. Ten days after second boost, naïve and optimally prime-boosted 
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Hsd:ND4 mice were infected via i.p. route with P. berghei–infected blood. When 
parasitemia reached <6% mice were injected with phenylhydrazine hydrochloride (60 
mg/Kg) (Santa Cruz Biotechnology, Dallas, Texas) to stimulate gametocytemia. Mice 
harboring circulating gametocytes (confirmed by Giemsa staining) were anesthetized 
and used to feed 100 3-day old An. gambiae female mosquitoes for 20 minutes. After 
feeding, un-engorged mosquitoes were removed and engorged mosquitoes transferred to 
a cage and kept at 19oC and 8% (w/v) sucrose. Seven days after infection, mosquitoes 
were dissected and the midguts were stained with 0.2% mercurochrome and examined 
using light microscopy to count the number of oocysts. Two independent experiments 
were performed for each treatment.  Transmission blocking activity was calculated as 
the 𝑇𝑟𝑎𝑛𝑠𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 1− !"#$ # !!"#$%$ !"#!$%&!'()* !"#$%!"#$ # !!"#$%$ !" !"#$%"& !"#$% 𝑥100. 
4.2.9 Determining antibody titer with ELISA assays 
  Mice sera were collected and assayed for the presence of FREP1 specific IgG 
antibodies using ELISA. In brief, recombinant affinity-purified FREP1 was diluted to 
0.5µg/ml in 0.1M sodium phosphate (Na2HPO4), pH 9.0 binding buffer and used to coat 
96-well plate MediSorpTM plates (NUNC –Denmark) overnight at 4 oC. Wells were 
washed three times with 0.2% Tween 20 in PBS (PBST) and blocked with 2.5% bovine 
serum albumin (BSA) and 1% normal goat serum in PBS for 2 hrs at room temperature. 
Serum samples were prepared by 1:5 serial dilutions starting at 1:100 to 1:8x106, 50 µl 
were added into each wells and incubated at room temperature for 1 hr. Bound IgG 
antibodies were detected using AP-conjugated goat anti-mouse IgG (Sigma-Aldrich) at 
1:800 in blocking solution for 2 hrs at room temperature and visualized using p-
Nitrophenylphosphate (Sigma-Aldrich, St. Louis, MO) as the substrate. Absorbance at 
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450nm was measured using Epoch microplate spectrophotometer (Biotek, Winooski, 
VT). Antibody titer was expressed as endpoint titer, the highest dilution of serum that 
gives a reading above the cutoff (2x standard deviation of the signal generated from pre-
immune serum). 
4.2.10 Cross-reactivity of mouse FREP1 serum to human plasma fibrinogen 
  Human blood (AB+) was purchased from Oklahoma Blood Institute. Whole 
blood collected from donors were transferred into BD Vacutainer® blood collection 
tubes (Becton and Dickinson Company, Franklin Lakes, NJ) coated with 
ethylenediaminetetraacidic acid dipotassium salt dihydrate (K2EDTA) to prevent 
coagulation. Blood sample was centrifuged at 3,000x g for 5 minutes at 4ºC to separate 
plasma. 50µL of human plasma samples without dilution (1) or diluted 10-fold in PBS 
(2) were coated overnight at 4 ºC in a 96-well plate (Brand, Wertheim, Germany). 50µL 
insect cell-expressed recombinant FREP1 (0.5µg/ml) and BSA (10mg/ml) were coated 
as positive and negative controls respectively. Samples were diluted in 0.1M Na2HPO4 
(pH 9.0). Each well was then incubated with the following solutions at RT: 150 µl 
blocking buffer (2.5% BSA and 1% normal goat serum in PBS) for 2 hrs, 50 µl of anti-
FREP1 mouse serum (1:1,000), control mouse serum (1:1,000) and anti-FREP1 rabbit 
serum (1:2,000) diluted in blocking buffer for 1 hr, 50µL of alkaline phosphatase-
conjugated goat anti-mouse IgG (1:800) and goat anti-rabbit IgG (1:20,000) for 1.5 hrs. 
Wells were washed for 5 minutes with PBST three times between incubations. At the 
end, the samples were developed with 50 µl of p-Nitrophenylphosphate solution (Sigma-
Aldrich).  
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4.2.11 Immunofluorescence assays (IFA) 
Nonpermeabilized immunofluorescence assays were performed as described 
previously [11]. In brief, P. falciparum cultures, containing cells and parasites, were 
smeared on coverslips (Fisher Scientific, Waltham, MA) and fixed in 4% 
paraformaldehyde in PBS at room temperature for 30 minutes. After quenching with 
0.1M glycine in PBS, coverslips were blocked overnight at 4ºC in 2.5 % BSA and 1% 
normal goat serum in PBS (blocking solution). Cells were incubated for 2 hours at room 
temperature with High Five cell-expressed FBG (100µg/ml) in blocking solution. 
Sequentially, cells were incubated for 1 hour with mouse monoclonal anti-His antibody 
(1:1, 000) and Goat anti-mouse (1:1, 000) secondary antibody (Alexa Fluor® 555, Life 
Technologies, Inc., Carlsbad, CA) for 45 mins, both diluted in blocking solution. Cells 
were washed between each step three times for 5 mins in PBST. Cells in the control 
group were incubated with High Five expressed 100 µg/ml chloramphemicol 
acetyltransferase (CAT). Coverslips were mounted on glass slides using 20µL 
vectashield mounting media (Vector Laboratories, Burlingame, CA) and visualized 
using a Nikon Eclipse Ti fluorescence microscope. 
4.2.12 Alignment of FREP1 sequences from multiple species of anopheline mosquitoes 
 The orthologs of FREP1 in various anopheline species were obtained from the 
Vector-Base genome server [18]. The multiple sequence alignment of An. gambiae 
FREP1 with its orthologs was built using ClustalO program ver. 1.2.1[19] and visualized 
with Jalview [20].  
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4.2.13 Using ELISA approach to demonstrate that anti-FBG serum inhibits the interaction 
between FREP1 and parasites 
  15-day cultured P. falciparum NF54 cells were lysed in PBST. About 50µL of 
supernatant (2.0mg/ml) per well was used to coat a 96-well plate. Purified recombinant 
full-length FREP1 was mixed with pre-immune mouse serum (1:150) or anti-FBG 
serum (1:150, final titer: 1x104). BSA (2.5 mg/mL) was used as a negative control. The 
bound FREP1 in wells was probed with anti-N-FREP1 mouse serum (1:1000 dilution), 
followed by incubation with alkaline phosphatase-conjugated goat anti-mouse IgG 
(1:20,000). After developed with pNPP (Sigma), OD405 was measured using Epoch 
microplate reader. Three replicates were conducted. 
4.3 Results  
4.3.1 The FREP1 fibrinogen-like domain is highly conserved in anopheline 
mosquitoes 
We examined the FREP1 orthologs among anopheline mosquitoes to find 
conserved regions. We obtained 13 orthologs from major malaria vectors in Africa (An. 
gambiae, An. funestus, An. arabiensis, An. coluzzii, An. merus, and An. albumnus), 
South America (An. darlingi), Asia (An. sinesis, An. stephensi, An. minimus, and An. 
epiroticus), and Europe (An. atroparvus). The results from multi-sequence alignment 
revealed a highly conserved region between amino acids 463 and 677 of An. gambiae 
FREP1 (Fig. 4-1A).  
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Figure 4-1. Multiple sequence alignment of FREP1 from An. gambiae and other 
major malaria vectors. 
A: The overview of sequence alignments of FREP1 orthologs in Anopheles mosquitoes 
and human fibrinogens. B: Detailed alignment of conserved FBG domains. Dots and 
dashes are insertions or deletions. Colored letters depict conserved amino acids. 
 
Detailed analyses of this conserved region found that more than 90% of the 
protein sequences are identical among all 13 anopheline species (Fig. 4-1B), suggesting 
that antibodies raised against this domain might be able to block that transmission of 
multiple Plasmodium species to multiple Anopheles mosquitoes. Since this conserved 
region is a FBG domain, we also compared FREP1 with human fibrinogens α, β, and γ 
chains. Multiple sequence alignment found less than 10% identical sequences between 
the mosquito conserved FBG domain and human fibrinogens, supporting that 
vaccination with recombinant mosquito FREP1 or the FBG domain protein would be 
unlikely to trigger autoimmune reactions. 
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4.3.2 Rabbit Anti-FREP1 antibodies inhibit malaria transmission in P. berghei and 
P. vivax in Anopheles gambiae and Anopheles dirus respectively 
Previously, we reported that anti-FREP1 rabbit polyclonal antibodies effectively 
blocked P. falciparum in a major malaria vector, An. gambiae [11]. Since there is a 
highly conserved FBG domain among anopheline orthologs, we determined whether 
anti-FREP1 antibody would also inhibit transmission of other Plasmodium species to 
additional Anopheles species. To address this question, An. gambiae mosquitoes were 
fed with P. berghei infected blood mixed with rabbit anti-FREP1 serum (1:1 dilution, 
final titer 5x104), and subsequently examined the number of developing oocysts in 
mosquito midguts. Rabbit pre-immune serum was used as a negative control. The results 
showed that anti-FREP1 serum significantly reduced the number of P. berghei oocysts, 
compared with the control group that substituted anti-FREP1 serum with pre-immune 
serum (Fig. 4-2A). The average number of P. berghei oocysts per midgut significantly 
decreased from 10 in the control group to 3 in the experimental group (p<0.0001).  The 
results were consistent in two biological replicates.  
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Figure 4-2. Rabbit anti-FREP1 antiserum inhibits P. berghei and P. vivax infection 
of  An. gambiae and An. dirus mosquitoes, repectively. 
Control: Pre-immune rabbit serum was used. Experiment (Exp): anti-FREP1 rabbit 
serum was used. 
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Next we tested whether anti-FREP1 antibody could inhibit the transmission of 
another major human malaria pathogen, P. vivax, to another major malaria vector in 
Asia, An. dirus. P. vivax-infected blood (2 field isolates) was mixed with rabbit anti-
FREP1 serum (1:1 dilution, final titer 5x104) and fed to An. dirus. The results showed 
that the anti-FREP1 antibody significantly reduced the number of oocysts per midgut 
more than two folds compared to the control serum (Fig. 4-2B). Statistical analysis 
showed that the inhibitory effect of anti-FREP1 antibodies against P. vivax infection in 
An. dirus is significant (p <0.005). Together, these data support that anti-FREP1 
antibodies can block the transmission of multiple species of malaria parasites to multiple 
mosquito species. 
4.3.3 Experimental immunization of mice with FREP1 does not trigger toxicity or 
elicit antibodies that cross-react with human fibrinogen 
Our sequence alignment displayed a minor degree of homology between 
mosquito FREP1 and mammalian fibrinogens. Despite this, we also investigated 
whether immunization of mice with FREP1 causes any autoimmune response. We 
expressed the recombinant FREP1 protein in E. coli and insect cells and purified the 
recombinant proteins using Ni-NTA affinity columns [11]. For both E. coli and insect 
cell expressed recombinant FREP1, mice were immunized with a series of FREP1 doses 
(0.2, 2, or 20µg) and boosted with the same dose twice at three-week intervals. Pre-
immune human plasma coated ELISA assays were performed to assess the cross 
reactivity between anti-FREP1 polyclonal antibodies generated in mice and human 
blood plasma (human fibrinogens). 
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Figure 3-3. FREP1 immunizations do not trigger autoimmune reactions against 
mammalian or human fibrinogens and are nontoxic to mice. 
A: Mouse anti-FREP1 antiserum does not cross-react with human fibrinogens, and no 
autoimmunity was induced either. P: coated with insect cell-expressed recombinant 
FREP1; 1: coated with human plasma; 2: coated with 10-fold diluted human plasma; N: 
wells coated with BSA. B: The serum ALT activity does not change significantly 
between the FREP1-immunized mice and control mice.  I-: insect cell expressed 
recombinant FREP1. E-: E. coli expressed recombinant FREP1. 
 
 
Wells coated with bovine serum albumin or insect cell-expressed recombinant 
FREP1 were used as negative and positive controls, respectively. The results showed no 
cross-specific recognition between the anti-FREP1 antibodies generated by E. coli or 
insect cell expressed FREP1 to human plasma fibrinogen (Fig. 4-3A). 
Complementarily, we examined whether immunization with recombinant FREP1 
triggered toxicity or caused inflammatory immunopathology in mammals by examining 
the activities of alanine aminotransferase (ALT) in the immunized mice. The positive 
control was the blood from P. yoelii-infected mice, which exhibited high levels of ALT, 
characteristic of inflammation and liver damage (Fig. 4-3B). Notably, the levels of ALT 
activity in the mice injected with E. coli- or insect cell-expressed FREP1 protein was 
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similar to the baseline activity observed in naïve mouse serum (p>0.38), supporting that 
immunization of FREP1 does not cause inflammatory autoimmune or toxicity responses. 
4.3.4 Immunizing mice with FBG inhibits the transmission of P. berghei to 
mosquitoes in vivo using direct feeding on mice 
Although anti-FREP1 antibodies block the transmission of multiple Plasmodium 
species to multiple Anopheles species, only FBG domains are conserved among 
anopheline mosquitoes. Therefore, we next determined whether the highly conserved 
FREP1 FBG domain alone was an effective TBV antigen in vivo and in vitro. We cloned 
the FREP1 FBG domain (from 463 to 729 aa) and expressed it in E. coli.  Mice were 
immunized with purified FBG protein mixed with Alhydrogel adjuvant using an optimal 
prime-boost regimen. High-titer antibody levels (3x106 on average) against FBG were 
achieved in anti-serum (Fig. 4-4A). Mice in the control group were immunized with 
buffer mixed with Alhydrogel under the same regimen. Ten days after second boost, 
mice were infected with P. berghei, and were further used to infect An. gambiae 
directly.  Results showed that An. gambiae mosquitoes fed on the FBG-immunized mice 
had 4.2 and 3.5 oocysts per midgut on average in two experiments, which was 
significantly (p<0.0004) fewer than mosquitoes fed on mock-immunized mice that had 
16.7 and 19.8 oocysts on average in two experiments (Fig. 4-4B). Anti-FBG antibodies 
reduced the number of oocysts by 75% and 82% in these two independent replicates. We 
collected the mouse sera and measured titers of anti-FBG antibodies by ELISA endpoint 
titer assays.  
 
89 
 
Figure 4-4. Immunization of mice with purified FBG formulated with Alhydrogel 
inhibits P. berghei transmission to An. gambiae in in vivo studies and P. falciparum 
transmission to An. gambiae in vitro with SMFA. 
A: Endpoint-titer shows recombinant FBG is highly immunogenic B: in vivo studies 
results of direct feeding assays using two FBG-immune mice and two control mice 
showed the transmission-blocking activity of in vivo generated anti-FBG antibody 
response against P. berghei to An. gambiae mosquitoes. C: In in vitro studies, serum 
collected from FBG-immune mice also blocks P. falciparum (NF54 strain) infection to 
An. gambiae mosquitoes. Control or anti-FREP1 immunized mouse sera were mixed 
with human serum (1:4 ratio) and mixed with P. falciparum-infected packed human 
blood prior to its use in SMFA. The final anti-FBG antibody titer was 4x105.  
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4.3.5 Anti-FBG anti-serum inhibits the transmission of P. falciparum to mosquitoes 
in membrane-feeding assays 
To test whether mouse anti-FBG serum also exhibits transmission-blocking 
activity against P. falciparum, we added immune serum from immunized mice to P. 
falciparum-infected blood containing gametocytes and fed to mosquitoes using SMFA. 
The average number of oocyst per midgut was reduced from 17.4 and 7.2 in control 
groups to 3.3 and 1.2 in experimental groups, respectively, in two replicates (Fig. 4-4C). 
The anti-FBG serum significantly (p<0.0001) reduced the number of oocysts of P. 
falciparum by more than 81%. These in vivo and in vitro experiments demonstrate that 
the conserved FBG alone is a potent universal TBV antigen. 
Since anti-FBG anti-serum blocks Plasmodium transmission and FBG domain of 
FREP1 binds Plasmodium parasites, anti-FBG anti-serum should inhibit the interaction 
between FREP1 and parasites. We used ELISA and IFA to test this hypothesis. For 
ELISA, we coated a plate with the lysate of sexual stage parasites. The purified FREP1 
and anti-FBG serum were mixed and added to coated wells. 
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4.3.6 Anti-FBG antibodies prevent FREP1 from binding to Plasmodium parasites 
 
Figure 4-5. ELISA assays demonstrate that anti-FBG mouse serum prevents 
FREP1 from binding to Plasmodium parasites. 
 
The normal mouse serum replacing anti-FBG anti-serum was used as a negative 
control (no blocking activity). Incubation of coated plate without FREP1 was used as a 
positive control (completely blocked). Antibodies against N-FREP1 protein quantified 
the parasite-bound FREP1. Results indicated that anti-FBG anti-serum significantly 
reduced binding signals between FREP1 and parasites (Fig. 4-5). In order to confirm 
that anti-FBG anti-serum blocks the interaction between FREP1 and sexual stage 
parasites, IFA assays were conducted. As shown in Fig. 4-6, P. falciparum gametocytes 
and ookinetes incubated with FREP1 mixed with anti-FBG serum have much weaker 
signals than those mixed with pre-immune mouse serum.  
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Figure 4-6. IFA assays found that anti-FBG serum prevents FREP1 from binding 
to parasites. 
 
4.4 Discussion 
Malaria TBVs are novel approaches for malaria control. However, there are few 
efficacious antigen targets that have been described. We identified a novel Plasmodium 
invasion pathway, e.g. FREP1 mediated Plasmodium invasion through direct binding to 
P. falciparum gametocytes and ookinetes [11]. Since FREP1 localizes in the mosquito 
midgut peritrophic matrix, it is readily accessible to antibodies in co-ingested blood. 
Therefore, mosquito FREP1 is an ideal target for a TBV. 
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One of the scientific hurdles in developing TBVs is that malaria is caused by 
multiple species of parasites transmitted by multiple species of mosquito vectors.  
Identification of an antigen with the potential to limit the transmission of multiple major 
parasite species by multiple major vectors is critical for developing a successful TBV. 
Previously, we demonstrated that anti-FREP1 antibody effectively inhibited the 
infection of An. gambiae, a major malaria vector in Africa, by P. falciparum, a major 
human malaria pathogen [11]. Here, we show that anti-FREP1 antibody also 
significantly reduced the transmission of P. vivax, another important human malaria 
pathogen by An. dirus, another major mosquito malaria vector in Asia. Moreover, our 
data show that anti-FREP1 antibodies also inhibit transmission of P. berghei to 
mosquitoes. P. berghei is a distantly related parasite causing rodent malaria. Together, 
we propose that FREP1 is an excellent candidate as a universal TBV antigen.  
We examined the orthologs of FREP1 in anopheline mosquitoes. The length of 
FREP1 orthologs is various, from 311 amino acids in An. dirus to 738 amino acids in 
An. gambiae. However, they share a highly conserved FBG domain that is about 210 
amino acids in length. Notably, antibodies against FREP1 FBG domain effectively 
blocked the transmission of P. berghei and P. falciparum to mosquitoes. Because the E. 
coli-expressed FREP1 FBG domain used for immunization was purified under a 
denaturing condition and the transmission-blocking activity of anti-FBG antibody was 
functional a fully folded FBG is not required as a vaccine antigen. This is an advantage 
for this highly conserved mosquito midgut antigen [3, 13, 14]. In chapter 3, we 
discovered that FBG domain in FREP1 binds Plasmodium gametocytes and ookinetes. 
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Here, we verified that anti-FBG serum prevents parasites from binding to FREP1, which 
explains the molecular mechanisms of FREP1 FBG as a universal TBV antigen.  
We also investigated the immunogenicity, toxicity and autoimmunity following 
FREP1 and FBG immunization of mice. Immunization with either E. coli or insect cell 
expressed FREP1 proteins elicited high titers of antibodies, supporting that recombinant 
FREP1 and FBG is highly immunogenic. High-titer functional antibodies are required 
for TBVs. The principle mode of action of this approach depends on high levels of 
antibodies circulating in the blood of the human host at the time that the malaria 
mosquito vector takes a bite, in order for the antibodies to prevent parasites from 
invading mosquito guts.  Importantly, FBG immunization of mice with a clinically 
relevant adjuvant (Alhydrogel) did not induce autoimmune reactions, immunopathology, 
or elicited cross-reactive antibodies against endogenous or human fibrinogens.  
Our data collectively demonstrate that FREP1-mediated Plasmodium invasion 
pathway is highly conserved in Plasmodium parasites and Anopheles mosquitoes. 
Indeed, a cocktail of vaccine antigens that includes both FBG and the parasite expressed 
FREP1-binding partners would be predicted to synergistically increase transmission-
blocking efficacy and potentially enable the vaccines to completely inhibit malaria 
transmission.   
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